Peptide trials recruiting now
Every study on ClinicalTrials.gov that is recruiting, not yet recruiting, or enrolling by invitation and tests a peptide in our encyclopedia, read from the registry on 2026-11-18. For each one: its phase, whether people are randomized, who is blinded, what the peptide is compared with, how many people it plans to enroll, its primary outcome, where it runs and who sponsors it. A registered trial is a plan, not a result: it says what researchers will measure, not what the peptide does. Whether you can join is decided by each study's own eligibility rules and its listed contacts on ClinicalTrials.gov. Nothing here is medical advice, and Grey Peptides sells nothing.
322 studies listed in full across 96 peptides
Peptides not approved anywhere (68)
Peptides with no approval for any use in any country we have found, where a registered trial is the strongest evidence still to come. Every open study is listed.
Eloralintide 15 open studies, 11 placebo-controlled
A Study of EloraTZP in Adult Participants With Obesity Without Type 2 Diabetes
- Primary outcome
- Percent Change from Baseline in Body Weight (Baseline, Week 100)
- Where
- Argentina, China, Germany, India, Japan, Puerto Rico and 3 more
- Sponsor (as registered)
- Eli Lilly and Company
- Dates
- Start 2026-12 · record updated 2026-11-17
- Primary outcome
- Percent Change from Baseline in Body Weight (Baseline, Week 64) +1 more
- Where
- Argentina, Australia, Brazil, Canada, China, Czechia and 15 more
- Sponsor (as registered)
- Eli Lilly and Company
- Dates
- Start 2026-12 · record updated 2026-11-17
A Study Assessing Eloralintide (LY3841136) in Healthy Participants
- Primary outcome
- Pharmacokinetics (PK): Area Under the Plasma Concentration Curve (AUC) of LY3841136 Administered Subcutaneously (SC) (Baseline through Day 57) +1 more
- Where
- Singapore, United States
- Sponsor (as registered)
- Eli Lilly and Company
- Dates
- Start 2026-11 · record updated 2026-11-13
A Study of EloraTZP in Adult Participants With Obesity or Overweight and Type 2 Diabetes
- Primary outcome
- Percent Change from Baseline in Body Weight (Baseline, Week 100)
- Where
- Brazil, China, Germany, Japan, Puerto Rico, Romania and 4 more
- Sponsor (as registered)
- Eli Lilly and Company
- Dates
- Start 2026-10-16 · record updated 2026-11-04
A Study of Macupatide (LY3532226) in Participants With Obesity or Overweight Without Type 2 Diabetes
- Primary outcome
- Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration (End of Study (Week 25))
- Where
- Japan
- Sponsor (as registered)
- Eli Lilly and Company
- Dates
- Start 2026-10 · record updated 2026-08-14
A Study of Eloralintide (LY3841136) in Female Participants With Obesity or Overweight
- Primary outcome
- Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve from Time Zero to Infinity (AUC[0-inf]) of Ethinyl Estradiol and Levonorgestrel (Baseline through Day 128) +2 more
- Where
- United States
- Sponsor (as registered)
- Eli Lilly and Company
- Dates
- Start 2026-09-15 · record updated 2026-10-08
A Study of Eloralintide (LY3841136) in Participants With Overweight or Obesity
- Primary outcome
- Change From Baseline In Hyperinsulinemic Euglycemic Clamp (HEC) Predicted Clamp-Derived Insulin Sensitivity (M-value) (Baseline, Week 24)
- Where
- Germany, Sweden
- Sponsor (as registered)
- Eli Lilly and Company
- Dates
- Start 2026-06-24 · record updated 2026-07-16
- Primary outcome
- Percent Change from Baseline in Body Weight (Baseline, Week 36)
- Where
- United States
- Sponsor (as registered)
- Eli Lilly and Company
- Dates
- Start 2026-05-15 · record updated 2026-10-08
- Primary outcome
- Percent Change from Baseline in Body Weight (Baseline, Week 64)
- Where
- Australia, Belgium, Brazil, China, Czechia, India and 8 more
- Sponsor (as registered)
- Eli Lilly and Company
- Dates
- Start 2026-02-10 · record updated 2026-11-04
- Primary outcome
- Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Zero to Infinity AUC(0-∞) of LY3841136 (Predose on Day 1 up to Day 71) +1 more
- Where
- Hungary, United States
- Sponsor (as registered)
- Eli Lilly and Company
- Dates
- Start 2026-02-10 · record updated 2026-06-04
- Primary outcome
- Percent Change from Baseline in Body Weight (Baseline, Week 64) +1 more
- Where
- Australia, Brazil, Canada, China, Germany, India and 5 more
- Sponsor (as registered)
- Eli Lilly and Company
- Dates
- Start 2026-02-10 · record updated 2026-11-04
- Primary outcome
- Percent Change from Baseline in Body Weight (Baseline, Week 64) +1 more
- Where
- Argentina, Belgium, Canada, China, Czechia, Denmark and 7 more
- Sponsor (as registered)
- Eli Lilly and Company
- Dates
- Start 2026-02-09 · record updated 2026-11-04
- Primary outcome
- Percent Change from Baseline in Body Weight (Baseline, Week 64)
- Where
- Argentina, Australia, Belgium, Brazil, Canada, China and 9 more
- Sponsor (as registered)
- Eli Lilly and Company
- Dates
- Start 2026-02-06 · record updated 2026-09-22
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
- Primary outcome
- Percent Change from Baseline in Body Weight (Baseline, Week 64)
- Where
- China, Czechia, Germany, India, Japan, Mexico and 7 more
- Sponsor (as registered)
- Eli Lilly and Company
- Dates
- Start 2025-12-15 · record updated 2026-11-04
- Primary outcome
- Number of Participants Allocated to Each ISA (Baseline to Week 6)
- Where
- Argentina, United States
- Sponsor (as registered)
- Eli Lilly and Company
- Dates
- Start 2023-11-17 · record updated 2026-10-07
Glutathione 12 open studies, 6 placebo-controlled
S-Acetyl Glutathione and Performance Recovery in Soccer
- Primary outcome
- Change in creatine kinase levels (Day 1, day 7, day 9, day 10 and day 11) +12 more
- Where
- Greece
- Sponsor (as registered)
- University of Thessaly
- Dates
- Start 2026-09-01 · record updated 2026-07-08
- Primary outcome
- Change from Baseline in Total Autism Treatment Evaluation Checklist (ATEC) Score at Month 6 (Baseline and Month 6)
- Where
- United States
- Sponsor (as registered)
- Greater Atlanta Integrative Pediatrics
- Dates
- Start 2026-06-01 · record updated 2026-06-03
Adia Med of Winter Park LLC Chronic Kidney Disease Research Study
- Primary outcome
- Change from Baseline in Estimated Glomerular Filtration Rate (eGFR) (Baseline to Month 6) +1 more
- Where
- United States
- Sponsor (as registered)
- Adia Med of Winter Park LLC
- Dates
- Start 2026-05-18 · record updated 2026-06-17
Adia Med of Winter Park LLC Autism Spectrum Disorder Research Study
- Primary outcome
- Change from Baseline in Total Autism Treatment Evaluation Checklist (ATEC) Score at Month 6 (Baseline and Month 6)
- Where
- United States
- Sponsor (as registered)
- Adia Med of Winter Park LLC
- Dates
- Start 2026-05-01 · record updated 2026-09-22
- Primary outcome
- compare reduction of Melasma Area and Severity Index (MASI) score in any treatment modalities (From baseline to 12 weeks)
- Where
- Not listed
- Sponsor (as registered)
- Assiut University
- Dates
- Start 2026-02 · record updated 2026-03-04
Efficacy Evaluation Study of Vitamin C and Glutathione Liquid Sachet
- Primary outcome
- The change of skin tone (Change from Baseline skin tone at 12 weeks) +2 more
- Where
- Taiwan
- Sponsor (as registered)
- TCI Co., Ltd.
- Dates
- Start 2026-01-24 · record updated 2026-02-04
Gingival Hyperpigmentation Treatment
- Primary outcome
- Degree of gingival pigmentation by Takashi index (Hanioka et al., 2005) (baseline: before surgery/injection (day1), after 1 mon ,3 mon ,6 mon and 9 month) +1 more
- Where
- Egypt
- Sponsor (as registered)
- Cairo University
- Dates
- Start 2025-08-01 · record updated 2026-05-19
Glucocorticoids for Acute Drug Induced Liver Injury With Hyperbilirubinemia
- Primary outcome
- Improvement of DILI on the second week (2 weeks)
- Where
- China
- Sponsor (as registered)
- General Hospital of Shenyang Military Region
- Dates
- Start 2025-06-24 · record updated 2025-12-18
Randomized Trial of Glutathione With Anti-PD-1 and Chemotherapy in Advanced NSCLC
- Primary outcome
- Progression-Free Survival (PFS) (From randomization until the first documented disease progression or death from any cause, whichever occurs first, assessed up to 24 months.") +1 more
- Where
- China
- Sponsor (as registered)
- The First Affiliated Hospital of Zhengzhou University
- Dates
- Start 2025-06-01 · record updated 2025-08-07
Ultrasound-Enhanced Delivery of Compound TXA Solution in Melasma
- Primary outcome
- percentage reduction in hemi-MASI (From enrollment to the end of treatment at 8 weeks, and 4&12 weeks after the final intervention)
- Where
- China
- Sponsor (as registered)
- The First Affiliated Hospital with Nanjing Medical University
- Dates
- Start 2024-10-20 · record updated 2025-11-25
Prevent Cardiac Surgery Associated AKI Trial
- Primary outcome
- AKI incidence reduction (28 days) +1 more
- Where
- United States
- Sponsor (as registered)
- George Washington University
- Dates
- Start 2024-07-18 · record updated 2026-10-14
Intranasal Insulin and Glutathione as an Add-On Therapy in Parkinson's Disease
- Primary outcome
- Verbal Fluency (24 Weeks)
- Where
- United States
- Sponsor (as registered)
- Gateway Institute for Brain Research
- Dates
- Start 2022-02-07 · record updated 2026-07-22
UBT251 11 open studies, 6 placebo-controlled
UBT251 Injection Phase Ⅲ Study (OSA-NPAP)
- Primary outcome
- Change from baseline in the Apnea-Hypopnea Index (AHI) (Baseline, Week 52)
- Where
- Not listed
- Sponsor (as registered)
- The United Bio-Technology (Hengqin) Co., Ltd.
- Dates
- Start 2026-12-01 · record updated 2026-11-03
UBT251 Injection Phase Ⅲ Study (OSA-PAP)
- Primary outcome
- Change from baseline in the Apnea-Hypopnea Index (AHI) (Baseline, Week 52)
- Where
- Not listed
- Sponsor (as registered)
- The United Bio-Technology (Hengqin) Co., Ltd.
- Dates
- Start 2026-10-10 · record updated 2026-09-08
- Primary outcome
- HbA1c (Week 40)
- Where
- China
- Sponsor (as registered)
- The United Bio-Technology (Hengqin) Co., Ltd.
- Dates
- Start 2026-09-07 · record updated 2026-09-15
- Primary outcome
- HbA1c (Week 40)
- Where
- China
- Sponsor (as registered)
- The United Bio-Technology (Hengqin) Co., Ltd.
- Dates
- Start 2026-09-07 · record updated 2026-09-14
- Primary outcome
- AUC,EE,SS: The area under the EE plasma concentration time curve during a dosing interval at steady state (From pre-dose on Day 8 up to 157 days) +1 more
- Where
- Canada
- Sponsor (as registered)
- Novo Nordisk A/S
- Dates
- Start 2026-07-17 · record updated 2026-08-25
- Primary outcome
- AUC0-∞,s-warfarin: The area under the plasma s-warfarin concentration-time curve extrapolated to infinity after single dose (From pre-dose on Day 1 up to 156 days) +2 more
- Where
- United States
- Sponsor (as registered)
- Novo Nordisk A/S
- Dates
- Start 2026-07-15 · record updated 2026-08-18
- Primary outcome
- UBT251: Change in glycated haemoglobin (HbA1c) (From baseline (week 0) to 12 weeks on a given maintenance dose (week 16, 28 and 40))
- Where
- Australia, Germany, Hungary, Poland, Romania, Slovakia and 3 more
- Sponsor (as registered)
- Novo Nordisk A/S
- Dates
- Start 2026-06-22 · record updated 2026-10-07
Phase I Drug-Drug Interaction Study of UBT251 Injection in Participants With Overweight or Obesity
- Primary outcome
- Area under plasma concentration-time curve of metformin (AUC0-τ) and S-warfarin, R-warfarin (AUC0-t, AUC0-∞) (From time 0 to 30 hours (metformin, post last dose) and 168 hours (S-warfarin, R-warfarin) after respective doses) +1 more
- Where
- China
- Sponsor (as registered)
- The United Bio-Technology (Hengqin) Co., Ltd.
- Dates
- Start 2026-05-27 · record updated 2026-08-25
- Primary outcome
- Part A - Number of treatment emergent adverse events (TEAEs) (From baseline (week 0) to end of study (week 33)) +2 more
- Where
- Canada, United States
- Sponsor (as registered)
- Novo Nordisk A/S
- Dates
- Start 2026-02-02 · record updated 2026-04-21
A Study of UBT251 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH)
- Primary outcome
- Percentage of Participants With MASH resolution With no Worsening of Fibrosis on Liver Histology (Baseline, Week 48)
- Where
- China
- Sponsor (as registered)
- The United Bio-Technology (Hengqin) Co., Ltd.
- Dates
- Start 2025-09-30 · record updated 2026-11-03
UBT251 Injection Phase II Clinical Study (CKD)
- Primary outcome
- log-transformed urinary albumin:creatinine ratio(UACR) (24 weeks)
- Where
- China
- Sponsor (as registered)
- The United Bio-Technology (Hengqin) Co., Ltd.
- Dates
- Start 2025-09-01 · record updated 2026-11-03
Cagrilintide 10 open studies, 10 placebo-controlled
- Primary outcome
- CagriSema versus Placebo : Change in in-office systolic blood pressure (SBP) (From baseline (week 0) to week 32)
- Where
- Argentina, Australia, Belgium, Brazil, Bulgaria, Canada and 13 more
- Sponsor (as registered)
- Novo Nordisk A/S
- Dates
- Start 2026-11-11 · record updated 2026-11-05
- Primary outcome
- Change in glycated haemoglobin (HbA1c) (From baseline (week 0) to end of double-blinded treatment (week 26))
- Where
- Argentina, Brazil, Colombia, India, Israel, Malaysia and 4 more
- Sponsor (as registered)
- Novo Nordisk A/S
- Dates
- Start 2026-08-04 · record updated 2026-10-19
- Primary outcome
- Relative change in body weight (From baseline (week 0) to end of treatment (week 26))
- Where
- Greece, Hungary, Portugal, Serbia, Sweden, United States
- Sponsor (as registered)
- Novo Nordisk A/S
- Dates
- Start 2026-08-04 · record updated 2026-09-04
- Primary outcome
- Percentage of participants on standard dose or higher dose (yes/no) of cagrilintide and placebo (At week 26)
- Where
- United States
- Sponsor (as registered)
- Novo Nordisk A/S
- Dates
- Start 2026-05-29 · record updated 2026-10-19
- Primary outcome
- AUC,ss: area under the total cagrilintide concentration-time curve at steady state after 5th dosing of cagrilintide s.c. (Day 113 (pre-dose) to Day 120 (post-dose)) +1 more
- Where
- Germany
- Sponsor (as registered)
- Novo Nordisk A/S
- Dates
- Start 2026-05-18 · record updated 2026-06-26
- Primary outcome
- Relative change in total energy intake across ad libitum breakfast, lunch, evening meal and snack box (From baseline (Day 2) to end of treatment (Day 127))
- Where
- Germany
- Sponsor (as registered)
- Novo Nordisk A/S
- Dates
- Start 2026-04-30 · record updated 2026-05-15
- Primary outcome
- Change in insulin-stimulated fluorodeoxyglucose (FDG) uptake in skeletal muscle (Baseline to Week 51)
- Where
- Denmark
- Sponsor (as registered)
- Novo Nordisk A/S
- Dates
- Start 2026-04-10 · record updated 2026-05-07
- Primary outcome
- Number of Treatment Emergent Adverse Events (TEAEs) nausea, vomiting and diarrhoea (From first investigational medicinal products (IMP) administration (visit 2, day 1 or visit 9, day 74) to the end of treatment visit (Visit 2, day 16 or Visit 9, day 89))
- Where
- United Kingdom
- Sponsor (as registered)
- Novo Nordisk A/S
- Dates
- Start 2026-02-09 · record updated 2026-04-13
- Primary outcome
- Relative change in body mass index (BMI) (Baseline (week 0), week 68)
- Where
- Australia, Austria, Belgium, Bulgaria, China, Colombia and 20 more
- Sponsor (as registered)
- Novo Nordisk A/S
- Dates
- Start 2026-01-08 · record updated 2026-09-30
The Role of the Amylin Analogue Cagrilintide in Bone Metabolism
- Primary outcome
- Relative change in volumetric bone mineral density (vBMD) of the total hip assessed by quantitative computed tomography (QCT) (From baseline to end of treatment (week 68))
- Where
- Denmark
- Sponsor (as registered)
- Novo Nordisk A/S
- Dates
- Start 2025-06-12 · record updated 2026-09-10
HRS-9531 9 open studies, 6 placebo-controlled
- Primary outcome
- Percent Change from Baseline in Liver Fat Content by Magnetic Resonance Imaging - Proton Density Fat Fraction (MRI-PDFF) (Baseline, Week 32)
- Where
- China
- Sponsor (as registered)
- Fujian Shengdi Pharmaceutical Co., Ltd.
- Dates
- Start 2026-08-14 · record updated 2026-08-26
- Primary outcome
- Percentage change from baseline in body weight after 52 weeks of treatment (After 52 weeks of treatment.) +1 more
- Where
- China
- Sponsor (as registered)
- Fujian Shengdi Pharmaceutical Co., Ltd.
- Dates
- Start 2026-07-24 · record updated 2026-08-13
- Primary outcome
- Change in glycated hemoglobin (HbA1c) relative to baseline (Week 20.)
- Where
- China
- Sponsor (as registered)
- Fujian Shengdi Pharmaceutical Co., Ltd.
- Dates
- Start 2026-07-14 · record updated 2026-07-23
- Primary outcome
- AUCtau (0-24 hours after the 10th dosing.)
- Where
- China
- Sponsor (as registered)
- Fujian Shengdi Pharmaceutical Co., Ltd.
- Dates
- Start 2026-07 · record updated 2026-06-24
- Primary outcome
- The time from randomization to the first occurrence of the MACE-3 composite endpoint (approximately up to 61 months of treatment)
- Where
- China
- Sponsor (as registered)
- Fujian Shengdi Pharmaceutical Co., Ltd.
- Dates
- Start 2026-05-29 · record updated 2026-09-08
- Primary outcome
- Maximum concentration (Cmax) (Post-dose from Day 1 to Day 29.) +2 more
- Where
- China
- Sponsor (as registered)
- Fujian Shengdi Pharmaceutical Co., Ltd.
- Dates
- Start 2026-05-26 · record updated 2026-06-01
- Primary outcome
- Area under the curve from Time Zero to Time of last quantifiable concentration (AUCtau) (From Day 14 to Day 15.) +2 more
- Where
- China
- Sponsor (as registered)
- Fujian Shengdi Pharmaceutical Co., Ltd.
- Dates
- Start 2025-10-15 · record updated 2025-11-17
Efficacy and Safety of HRS9531 in Participants With Type 2 Diabetes Treated With Basal Insulin
- Primary outcome
- Change in HbA1c (from baseline to Week 40)
- Where
- China
- Sponsor (as registered)
- Fujian Shengdi Pharmaceutical Co., Ltd.
- Dates
- Start 2025-07-25 · record updated 2026-01-02
- Primary outcome
- Percentage Change in AHI from Baseline at Week 52 of Treatment (52week)
- Where
- China
- Sponsor (as registered)
- Fujian Shengdi Pharmaceutical Co., Ltd.
- Dates
- Start 2025-07-25 · record updated 2025-11-17
Maridebart cafraglutide 9 open studies, 3 placebo-controlled
- Primary outcome
- Area Under the Plasma Concentration-time Curve Over a Dosing Interval (AUCtau) of Maridebart Cafraglutide (Up To 115 days) +1 more
- Where
- United States
- Sponsor (as registered)
- Amgen
- Dates
- Start 2026-11-13 · record updated 2026-11-02
- Primary outcome
- Area Under the Plasma Concentration-time Curve from Time 0 to 28 days post dose (AUC 0-28) of Maridebart Cafraglutide (Up to 113 days) +1 more
- Where
- Not listed
- Sponsor (as registered)
- Amgen
- Dates
- Start 2026-11-09 · record updated 2026-11-06
Maridebart Cafraglutide Versus Semaglutide in Participants With Type 2 Diabetes
- Primary outcome
- Change from Baseline in Hemoglobin A1c (HbA1c) at Week 68 [Non-inferiority] (Baseline to Week 68)
- Where
- Canada, United States
- Sponsor (as registered)
- Amgen
- Dates
- Start 2026-10-16 · record updated 2026-11-05
- Primary outcome
- Percentage of Participants Who Successfully Self-inject a Full Dose Among Those Who Attempted Injection at Each Home Administration (Weeks 12, 16, and 20) +1 more
- Where
- Puerto Rico, United States
- Sponsor (as registered)
- Amgen
- Dates
- Start 2026-10-15 · record updated 2026-11-09
- Primary outcome
- Area Under the Concentration-Time Curve From Time 0 Extrapolated to Infinity (AUCinf) of Maridebart Cafraglutide (Up to Day 120) +2 more
- Where
- Not listed
- Sponsor (as registered)
- Amgen
- Dates
- Start 2026-10-12 · record updated 2026-09-22
- Primary outcome
- Percent Change in Body Weight from Baseline of the Parent Trial (20210184) (Baseline of parent trial (20210184) to Week 48 of current trial) +1 more
- Where
- Canada, Japan, Puerto Rico, United Kingdom, United States
- Sponsor (as registered)
- Amgen
- Dates
- Start 2026-07-29 · record updated 2026-10-05
- Primary outcome
- Percent Change in Body Weight from Baseline of the Parent Trial (20210181) (Baseline of parent trial (20210181) to Week 48 of current trial) +1 more
- Where
- Australia, Canada, Japan, Puerto Rico, United States
- Sponsor (as registered)
- Amgen
- Dates
- Start 2026-07-23 · record updated 2026-10-05
- Primary outcome
- Percent Change from Baseline in Body Weight at Week 68 (Week 68)
- Where
- Puerto Rico, United States
- Sponsor (as registered)
- Amgen
- Dates
- Start 2026-05-11 · record updated 2026-11-17
- Primary outcome
- Time to First Occurrence of a Composite Endpoint Consisting of: CV Death or HF Events (Up to approximately 35 months)
- Where
- Argentina, Australia, Austria, Belgium, Brazil, Bulgaria and 29 more
- Sponsor (as registered)
- Amgen
- Dates
- Start 2025-06-25 · record updated 2026-10-29
Pentixafor 8 open studies
- Primary outcome
- To evaluate the concordance of tumoral lesions detected between [68Ga]Ga-PentixaFor PET-CT and [18F]FDG PET-CT, considered as the reference, performed at diagnosis (30 days)
- Where
- France
- Sponsor (as registered)
- Institut Cancerologie de l'Ouest
- Dates
- Start 2026-09-30 · record updated 2026-06-18
Diagnostic Value of CXCR4-targeted PET/CT in ACTH-dependent and Independent Cushing's Syndrome
- Primary outcome
- Diagnostic value (From baseline PET/CT assessment to end of study (approximately 12 months))
- Where
- China
- Sponsor (as registered)
- Peking Union Medical College Hospital
- Dates
- Start 2025-12-25 · record updated 2026-11-03
18F-Pentixafor PET in Hematologic Malignancies
- Primary outcome
- Diagnostic efficacy (through study completion, an average of 1.5 year)
- Where
- China
- Sponsor (as registered)
- First Affiliated Hospital of Zhejiang University
- Dates
- Start 2025-07-01 · record updated 2025-08-14
- Primary outcome
- Diagnostic Accuracy of CXCR4-targeted [68Ga]Ga-PentixaFor PET/MR Imaging Compared to Standard of Care Imaging (Baseline (at initial staging))
- Where
- Canada
- Sponsor (as registered)
- University Health Network, Toronto
- Dates
- Start 2025-04-22 · record updated 2026-10-01
- Primary outcome
- Estimate the percent concordance of [68Ga]Ga-PentixaFor imaging with clinical diagnosis in identifying functional adrenal or extra-adrenal adenomas in hyperaldosteronism and hypercortisolism (Screening)
- Where
- United States
- Sponsor (as registered)
- National Cancer Institute (NCI)
- Dates
- Start 2024-09-23 · record updated 2026-10-22
- Primary outcome
- relevant biomarkers strongly associated with primary lateralized hyperaldosteronism (30 days after inclusion)
- Where
- France
- Sponsor (as registered)
- Assistance Publique - Hôpitaux de Paris
- Dates
- Start 2024-06 · record updated 2024-06-27
This registry record has not been updated since 2024-06-27, so its "not yet recruiting" status may be out of date.
CXCR4-targeted PET/CT Imaging in Hematological Malignancies
- Primary outcome
- Diagnostic Accuracy of 68Ga-pentixafor PET/CT Compared to 18F-FDG PET/CT in Hematological Malignancies (Two years) +4 more
- Where
- China
- Sponsor (as registered)
- Zhongnan Hospital
- Dates
- Start 2022-03-01 · record updated 2025-06-26
- Primary outcome
- SUVmax (through study completion, an average of 3 years) +1 more
- Where
- China
- Sponsor (as registered)
- First Affiliated Hospital of Fujian Medical University
- Dates
- Start 2020-08-07 · record updated 2026-07-21
Survodutide 8 open studies, 6 placebo-controlled
- Primary outcome
- Area under the concentration-time curve of the analyte in plasma at steady state over a uniform dosing interval τ (AUCτ,ss) (Up to Day 239) +1 more
- Where
- Germany
- Sponsor (as registered)
- Boehringer Ingelheim
- Dates
- Start 2026-12-03 · record updated 2026-11-16
- Primary outcome
- Composite average Z-score (dimensionless) at Week 76 of cardiac structural and functional parameters (At week 76)
- Where
- China, Germany, Spain, United Kingdom, United States
- Sponsor (as registered)
- Boehringer Ingelheim
- Dates
- Start 2026-11-18 · record updated 2026-11-12
- Primary outcome
- Percent change in body weight from baseline to Week 52 (At baseline and Week 52)
- Where
- United States
- Sponsor (as registered)
- Boehringer Ingelheim
- Dates
- Start 2026-11-07 · record updated 2026-10-27
- Primary outcome
- Percentage change in body weight from baseline to Week 52 (At baseline and Week 52)
- Where
- United Kingdom, United States
- Sponsor (as registered)
- Boehringer Ingelheim
- Dates
- Start 2026-10-31 · record updated 2026-10-30
A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar
- Primary outcome
- Absolute change in glycosylated haemoglobin A1c (HbA1c) (%) from baseline to Week 41 (At baseline and Week 41.)
- Where
- Australia, Canada, India, New Zealand, Puerto Rico, United States
- Sponsor (as registered)
- Boehringer Ingelheim
- Dates
- Start 2026-08-24 · record updated 2026-11-13
Albuminuria Reduction Study With Survodutide Treatment in Kidney Disease
- Primary outcome
- Change in first morning void UACR (From baseline to week 32/36)
- Where
- Not listed
- Sponsor (as registered)
- University Medical Center Groningen
- Dates
- Start 2026-03-02 · record updated 2025-10-03
- Primary outcome
- Time to first occurrence of any component of the composite clinical endpoint (at EoS) consisting of: all-cause mortality, liver transplant, hepatic decompensation events, worsening of MELD score to ≥15 and progression to CSPH (up to 4.5 years.)
- Where
- Argentina, Australia, Austria, Belgium, Brazil, Bulgaria and 31 more
- Sponsor (as registered)
- Boehringer Ingelheim
- Dates
- Start 2024-11-12 · record updated 2026-11-12
- Primary outcome
- Part 1: Resolution of MASH without worsening of liver fibrosis on MASH Clinical Research Network (CRN) fibrosis score (Baseline and at Week 52.) +2 more
- Where
- Argentina, Australia, Austria, Belgium, Brazil, Bulgaria and 31 more
- Sponsor (as registered)
- Boehringer Ingelheim
- Dates
- Start 2024-10-14 · record updated 2026-10-28
Avexitide 7 open studies, 2 placebo-controlled
Hypothalamic GLP-1 Response in Healthy Weight and Obesity
- Primary outcome
- Hypothalamic response to glucose ingestion during GLP-1 receptor blockade compared with saline (During the MRI scan on three test days) +1 more
- Where
- Denmark
- Sponsor (as registered)
- University of Copenhagen
- Dates
- Start 2026-10-01 · record updated 2026-11-02
The Effect of rs7903146 Genotype on Islet GLP-1 Production in Humans
- Primary outcome
- Change in fasting glucose (Change in average glucose concentration between -30 min and 0 min of each study day (saline day vs. exendin 9-39 day)) +1 more
- Where
- United States
- Sponsor (as registered)
- Mayo Clinic
- Dates
- Start 2026-10-01 · record updated 2026-01-30
Islet Function in Gestational Diabetes
- Primary outcome
- G50 (During pregnancy at approximately 26 to 32 weeks gestation and during the postpartum period at approximately 6 weeks to 3 months after delivery.)
- Where
- United States
- Sponsor (as registered)
- Mayo Clinic
- Dates
- Start 2026-09 · record updated 2026-09-08
The Role of Islet GLP-1 in the Pathogenesis of Prediabetes
- Primary outcome
- Alpha-cell responsivity to glucose as measured by G50 (0-240 minutes) +1 more
- Where
- United States
- Sponsor (as registered)
- Mayo Clinic
- Dates
- Start 2025-11-01 · record updated 2025-12-15
The Effects of Bariatric Surgeries on Glucose Metabolism
- Primary outcome
- Insulin levels measured after nutrient ingestion (Each study in the protocol is conducted up to seven hours with data collected at intervals specific to the individual study procedure.)
- Where
- United States
- Sponsor (as registered)
- The University of Texas Health Science Center at San Antonio
- Dates
- Start 2015-07 · record updated 2025-09-09
Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass Surgery
- Primary outcome
- Gut hormones and neural signaling contribution to insulin secretion rate and glucose tolerance (Each study of the protocol is conducted up to seven hours with data collected at intervals specific to the individual study procedure.)
- Where
- United States
- Sponsor (as registered)
- The University of Texas Health Science Center at San Antonio
- Dates
- Start 2009-10 · record updated 2025-09-09
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- Primary outcome
- The investigator measure glucose, islet and GI hormonal levels in response to meal ingestion as a composite measure and the percentage of contribution of GLP-1 contribution to postprandial insulin levels will also be calculated (up to 1 year (10 sessions))
- Where
- United States
- Sponsor (as registered)
- The University of Texas Health Science Center at San Antonio
- Dates
- Start 2005-11 · record updated 2025-09-09
AZD6234 6 open studies, 4 placebo-controlled
- Primary outcome
- Percent change in body weight from baseline at Week 64 (up to 64 weeks) +1 more
- Where
- China, India
- Sponsor (as registered)
- AstraZeneca
- Dates
- Start 2027-01-04 · record updated 2026-11-06
- Primary outcome
- Maximum observed plasma concentration (Cmax) (Plasma sample collection from pre dose to Day 22) +2 more
- Where
- United Kingdom
- Sponsor (as registered)
- AstraZeneca
- Dates
- Start 2026-11-09 · record updated 2026-11-02
- Primary outcome
- Percent change in body weight from baseline at 68 weeks of treatment (68 weeks)
- Where
- Argentina, Brazil, Canada, China, Denmark, Israel and 5 more
- Sponsor (as registered)
- AstraZeneca
- Dates
- Start 2026-08-24 · record updated 2026-11-09
- Primary outcome
- Percent change in body weight from baseline at 68 weeks of treatment. (68 weeks)
- Where
- Argentina, Australia, Canada, Chile, China, Germany and 10 more
- Sponsor (as registered)
- AstraZeneca
- Dates
- Start 2026-08-20 · record updated 2026-10-28
- Primary outcome
- Percent change in body weight from baseline at 68 weeks of treatment (68 weeks)
- Where
- Argentina, Australia, Brazil, Bulgaria, Canada, China and 10 more
- Sponsor (as registered)
- AstraZeneca
- Dates
- Start 2026-08-19 · record updated 2026-10-30
A Phase I Study to Investigate the Effect of Hepatic Impairment of AZD9550 and AZD6234
- Primary outcome
- PK parameters AUCinf (Day 0 through Day 56) +2 more
- Where
- United States
- Sponsor (as registered)
- AstraZeneca
- Dates
- Start 2026-03-20 · record updated 2026-10-22
Enicepatide 6 open studies, 5 placebo-controlled
- Primary outcome
- Time to First Occurrence of Any Component of 5-point (5P) MACE (From randomization up to 4.2 years)
- Where
- Not listed
- Sponsor (as registered)
- Hoffmann-La Roche
- Dates
- Start 2027-01-06 · record updated 2026-11-05
- Primary outcome
- Change From Baseline to Week 72 in Glycosylated Hemoglobin (HbA1c, %) (Baseline through Week 72)
- Where
- Not listed
- Sponsor (as registered)
- Hoffmann-La Roche
- Dates
- Start 2026-12-01 · record updated 2026-10-22
- Primary outcome
- Percentage Change in Body Weight between Arms 1 and 6 (From Baseline to Week 40)
- Where
- Not listed
- Sponsor (as registered)
- Hoffmann-La Roche
- Dates
- Start 2026-11-30 · record updated 2026-11-03
- Primary outcome
- Percent Change From Baseline in Body Weight at Week 52 (Baseline through Week 52)
- Where
- China
- Sponsor (as registered)
- Hoffmann-La Roche
- Dates
- Start 2026-07-03 · record updated 2026-11-05
- Primary outcome
- Percent (%) Change from Baseline in Body Weight at Week 72 (Baseline through Week 72)
- Where
- Argentina, Australia, Brazil, Canada, China, Czechia and 16 more
- Sponsor (as registered)
- Hoffmann-La Roche
- Dates
- Start 2026-03-23 · record updated 2026-11-09
- Primary outcome
- Percent (%) Change from Baseline in Body Weight at Week 72 (Baseline through Week 72)
- Where
- Argentina, Australia, Belgium, Brazil, Canada, China and 15 more
- Sponsor (as registered)
- Hoffmann-La Roche
- Dates
- Start 2026-03-16 · record updated 2026-11-09
GIP 6 open studies, 4 placebo-controlled
Postprandial Regulation of Bone Perfusion in Healthy Individuals
- Primary outcome
- Median Ki in the Femur (90 minutes)
- Where
- Denmark
- Sponsor (as registered)
- University of Copenhagen
- Dates
- Start 2026-07-19 · record updated 2026-07-09
- Primary outcome
- Change in GLP-1 induced nausea intensity (From enrollment to the end of treatment at up to 12 weeks.)
- Where
- Denmark
- Sponsor (as registered)
- University of Copenhagen
- Dates
- Start 2026-05-19 · record updated 2026-07-07
- Primary outcome
- Metabolic Rate of FDG (75 minuts)
- Where
- Denmark
- Sponsor (as registered)
- Copenhagen University Hospital, Rigshospitalet
- Dates
- Start 2026-03-12 · record updated 2026-10-27
- Primary outcome
- Number of Treatment Emergent Adverse Events (TEAEs) nausea, vomiting and diarrhoea (From first investigational medicinal products (IMP) administration (visit 2, day 1 or visit 9, day 74) to the end of treatment visit (Visit 2, day 16 or Visit 9, day 89))
- Where
- United Kingdom
- Sponsor (as registered)
- Novo Nordisk A/S
- Dates
- Start 2026-02-09 · record updated 2026-04-13
Effects of Endogenous GIP on Postprandial Blood Pressure in Healthy Individuals
- Primary outcome
- Postprandial systolic blood pressure change (delta SBP) (From -35 to 50 minutes)
- Where
- Denmark
- Sponsor (as registered)
- University Hospital, Gentofte, Copenhagen
- Dates
- Start 2025-05-21 · record updated 2025-09-08
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- Primary outcome
- Second-phase insulin response during GPA test (5 hours)
- Where
- United States
- Sponsor (as registered)
- University of Pennsylvania
- Dates
- Start 2013-05 · record updated 2026-01-14
FAP-2286 5 open studies
FAP PET/CT for Staging Patients With Breast Cancer
- Primary outcome
- Number of patients with nodal and distant metastases detected by [⁶⁸Ga]Ga-FAP-2286 PET/CT at baseline (pre-treatment staging) (Baseline (pre-treatment). Inclusion period 1 year.) +1 more
- Where
- Not listed
- Sponsor (as registered)
- Odense University Hospital
- Dates
- Start 2026-06-01 · record updated 2026-04-13
Phase II Trial of Lu-177 FAP-2286 in Patients With Carcinoma of Unknown Primary
- Primary outcome
- Overall Response Rate (ORR) (From start of treatment until end of follow-up (study completion- 2 years after the last patient has commenced treatment))
- Where
- Australia
- Sponsor (as registered)
- Peter MacCallum Cancer Centre, Australia
- Dates
- Start 2026-06 · record updated 2026-02-25
Application of ⁶⁸Ga-FXX489 (NNS309) PET/CT Imaging in Diagnosis of Tumor Diseases.
- Primary outcome
- Count of participants with treatment-emergent adverse events (Up to 3 days) +4 more
- Where
- China
- Sponsor (as registered)
- Yi Tian
- Dates
- Start 2025-09-11 · record updated 2026-04-03
A Study of 177Lu-FAP-2286 in Advanced Solid Tumors
- Primary outcome
- Phase 1: Dose-limiting toxicity (DLTs) (From first dose of study drug through at least 6-8 weeks after end of treatment (up to approximately 2 years)) +6 more
- Where
- Australia, Canada, France, Italy, Spain, United States
- Sponsor (as registered)
- Novartis Pharmaceuticals
- Dates
- Start 2021-07-30 · record updated 2026-07-24
Imaging of Solid Tumors Using FAP-2286
- Primary outcome
- Count of participants with treatment-emergent adverse events (Until end of day on the day of the injection (1 day total)) +4 more
- Where
- United States
- Sponsor (as registered)
- Thomas Hope
- Dates
- Start 2020-12-14 · record updated 2026-06-04
Lutropin alfa 5 open studies, 1 placebo-controlled
- Primary outcome
- Total number of oocytes retrieved (At approximately 36 to 38 hours after r-hCG administration (Day 4))
- Where
- Japan
- Sponsor (as registered)
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
- Dates
- Start 2026-02-05 · record updated 2026-10-29
- Primary outcome
- Anti-Mullerian Hormone (up to 18 months)
- Where
- Not listed
- Sponsor (as registered)
- Azienda Ospedaliero-Universitaria di Modena
- Dates
- Start 2025-03-17 · record updated 2025-03-19
Potential Benefit of r-hLH Addition in Patients Aged 35 to 40 Under Ovarian Stimulation Treatment
- Primary outcome
- Good quality embryo rate (cleavage stage) (Day 3 after fertilization)
- Where
- China
- Sponsor (as registered)
- Nanjing University
- Dates
- Start 2024-09-01 · record updated 2024-08-27
This registry record has not been updated since 2024-08-27, so its "not yet recruiting" status may be out of date.
- Primary outcome
- Proportion of cycles with no usable embryos (7 days after oocyte retrieval)
- Where
- China
- Sponsor (as registered)
- Nanjing University
- Dates
- Start 2024-02-01 · record updated 2025-08-19
FSH and LH Versus FSH Alone for Ovarian Stimulation in Non-hormone Sensitive Onco-fertility Patients
- Primary outcome
- Total number of mature (MII) oocytes available for cryopreservation (12hrs after egg retrieval)
- Where
- Not listed
- Sponsor (as registered)
- Ellen Greenblatt
- Dates
- Start 2024-02 · record updated 2024-01-29
This registry record has not been updated since 2024-01-29, so its "not yet recruiting" status may be out of date.
NAD+ 5 open studies, 4 placebo-controlled
- Primary outcome
- Change in NAD+ levels in whole blood from baseline to day 56 between the NAD+ supplement and placebo. (Day 0 to 56)
- Where
- Canada
- Sponsor (as registered)
- Reus Research
- Dates
- Start 2026-10-03 · record updated 2026-11-13
PEDIatric Cardiac Dysfunction Treated With Injectable Nicotinamide Adenine Dinucleotide
- Primary outcome
- Change in Left Ventricular Ejection Fraction (LVEF) from Baseline to 4 Weeks (Baseline to 4 weeks after treatment.)
- Where
- China
- Sponsor (as registered)
- Beijing Children's Hospital
- Dates
- Start 2026-10-01 · record updated 2026-09-24
- Primary outcome
- The primary objective is to evaluate the effect of NAD supplementation on objective sleep parameters via polysomnography (PSG). (From enrollment to the end of treatment at 8 weeks.)
- Where
- Norway
- Sponsor (as registered)
- Haukeland University Hospital
- Dates
- Start 2025-10-13 · record updated 2025-09-15
A Clinical Study of NAD in the Treatment of Immune Thrombocytopenia
- Primary outcome
- Evaluation of overall efficacy response after nicotinamide adenine dinucleotide/NMN treatment within 2 weeks ([Time Frame: 2 weeks]) +1 more
- Where
- China
- Sponsor (as registered)
- Institute of Hematology & Blood Diseases Hospital, China
- Dates
- Start 2025-01-15 · record updated 2025-08-05
Absorption and Tolerability of Injectable Administration of Niagen®+, as Compared to NAD+
- Primary outcome
- McGill Pain Questionnaire (1 minute after injection is complete) +1 more
- Where
- United States
- Sponsor (as registered)
- Nutraceuticals Research Institute
- Dates
- Start 2024-10-31 · record updated 2025-04-09
Petrelintide 5 open studies, 4 placebo-controlled
- Primary outcome
- Percentage Change in Body Weight between Arms 1 and 6 (From Baseline to Week 40)
- Where
- Not listed
- Sponsor (as registered)
- Hoffmann-La Roche
- Dates
- Start 2026-11-30 · record updated 2026-11-03
- Primary outcome
- Percentage Change in Body Weight from Baseline (From Baseline to Week 64)
- Where
- United States
- Sponsor (as registered)
- Hoffmann-La Roche
- Dates
- Start 2026-10-09 · record updated 2026-11-05
- Primary outcome
- Percentage Change in Body Weight from Baseline (From Baseline to Week 64)
- Where
- Taiwan, United Kingdom, United States
- Sponsor (as registered)
- Hoffmann-La Roche
- Dates
- Start 2026-09-30 · record updated 2026-11-16
- Primary outcome
- Percentage Change in Body Weight from Baseline (From Baseline to Week 64)
- Where
- United States
- Sponsor (as registered)
- Hoffmann-La Roche
- Dates
- Start 2026-09-30 · record updated 2026-11-05
Pharmacokinetics of Petrelintide in Participants With Impaired Hepatic Function
- Primary outcome
- Area Under the Plasma Concentration-time Curve (AUC) from Time Zero to Infinity (AUC0-inf) of Petrelintide (Day 1 (pre-dose) to Day 50 (Follow-up))
- Where
- Poland, Slovakia
- Sponsor (as registered)
- Zealand Pharma
- Dates
- Start 2026-05-18 · record updated 2026-07-06
CagriSema 4 open studies, 2 placebo-controlled
- Primary outcome
- CagriSema versus Placebo : Change in in-office systolic blood pressure (SBP) (From baseline (week 0) to week 32)
- Where
- Argentina, Australia, Belgium, Brazil, Bulgaria, Canada and 13 more
- Sponsor (as registered)
- Novo Nordisk A/S
- Dates
- Start 2026-11-11 · record updated 2026-11-05
Research Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to Cagrisema
- Primary outcome
- Number of treatment emergent adverse events (TEAEs) (From baseline (Week 0) to end of treatment (Week 16))
- Where
- United States
- Sponsor (as registered)
- Novo Nordisk A/S
- Dates
- Start 2026-09-16 · record updated 2026-09-30
- Primary outcome
- Change in glycated haemoglobin (HbA1c) (From baseline (week 0) to end of double-blinded treatment (week 26))
- Where
- Argentina, Brazil, Colombia, India, Israel, Malaysia and 4 more
- Sponsor (as registered)
- Novo Nordisk A/S
- Dates
- Start 2026-08-04 · record updated 2026-10-19
- Primary outcome
- Relative change in body weight (From randomisation (week 0) to end of treatment (week 72))
- Where
- Argentina, Australia, Austria, Belgium, Bulgaria, Canada and 13 more
- Sponsor (as registered)
- Novo Nordisk A/S
- Dates
- Start 2026-05-21 · record updated 2026-09-30
Amylin 3 open studies, 3 placebo-controlled
Pancreatic Polypeptide as a Modulator of Amylin- Induced Satiety in Healthy Humans
- Primary outcome
- Food intake (300 to 330 minutes)
- Where
- Denmark
- Sponsor (as registered)
- University Hospital, Gentofte, Copenhagen
- Dates
- Start 2026-04 · record updated 2026-04-01
Amylin-Induced Migraine Attacks Without Aura
- Primary outcome
- Incidence of migraine attacks without aura (12 hours)
- Where
- Denmark
- Sponsor (as registered)
- Danish Headache Center
- Dates
- Start 2026-02 · record updated 2026-01-14
Hypersensitivity to Amylin in Post-Traumatic Headache
- Primary outcome
- Incidence of migraine-like headache (12 hours)
- Where
- Denmark
- Sponsor (as registered)
- Danish Headache Center
- Dates
- Start 2026-02 · record updated 2026-01-14
Angiotensin-(1-7) 3 open studies, 3 placebo-controlled
Cardiovascular Effects of Angiotensin-(1-7) in Obesity Hypertension
- Primary outcome
- Change in Muscle Sympathetic Nerve Burst Rate (120 minutes) +1 more
- Where
- United States
- Sponsor (as registered)
- Milton S. Hershey Medical Center
- Dates
- Start 2025-01-23 · record updated 2026-09-24
Safety and Efficacy of Angiotensin (1-7) in Persons With Moderate to Severe Traumatic Brain Injury
- Primary outcome
- Number of participants with adverse events (At 21 days) +1 more
- Where
- United States
- Sponsor (as registered)
- University of Arizona
- Dates
- Start 2024-05-28 · record updated 2026-08-11
Metabolic Effects of Angiotensin-(1-7)
- Primary outcome
- Whole-Body Insulin Sensitivity (steady-state (time 90 to 120 minutes) during hyperinsulinemic-euglycemic clamp)
- Where
- United States
- Sponsor (as registered)
- Vanderbilt University
- Dates
- Start 2016-02 · record updated 2026-05-22
Kisspeptin-54 3 open studies
Kisspeptin to Quantify GnRH Neuronal Function in Health and Disease
- Primary outcome
- Difference in mean luteinizing hormone (LH) amplitude between cases and controls (Day of study visit (one to two hours))
- Where
- United States
- Sponsor (as registered)
- Stephanie B. Seminara, MD
- Dates
- Start 2026-03-10 · record updated 2026-07-13
Kisspeptin Administration Subcutaneously to Patients With Hypothalamic Amenorrhea
- Primary outcome
- Change of luteinizing hormone (LH) pulse amplitude (2 weeks)
- Where
- United States
- Sponsor (as registered)
- Stephanie B. Seminara, MD
- Dates
- Start 2025-12-09 · record updated 2026-07-13
Kisspeptin Administration Subcutaneously to Patients With IHH
- Primary outcome
- Average change in luteinizing hormone (LH) pulse amplitude (2 weeks)
- Where
- United States
- Sponsor (as registered)
- Stephanie B. Seminara, MD
- Dates
- Start 2023-02-03 · record updated 2026-07-13
Nesiritide 3 open studies, 2 placebo-controlled
rhBNP for Prevention of Cardiac Surgery-Associated Acute Kidney Injury (CSA-AKI)
- Primary outcome
- Incidence of acute kidney injury (AKI) within 7 days postoperatively, diagnosed per KDIGO criteria (Within 7 days after surgery, or until hospital discharge if earlier)
- Where
- China
- Sponsor (as registered)
- China National Center for Cardiovascular Diseases
- Dates
- Start 2026-05-01 · record updated 2026-06-01
Evaluation of the Efficacy of rhBNP in Patients With Diuretic Resistance After Cardiac Surgery
- Primary outcome
- the incidence of renal replacement therapy (From enrollment to discharge: at enrollment, the maintenance dose of rhBNP is 0.0075-0.01ug/kg/min, after 1 hour, 24 hours, 48 hours, and 72 hours post-medication.)
- Where
- China
- Sponsor (as registered)
- The First Affiliated Hospital of Anhui Medical University
- Dates
- Start 2025-08-01 · record updated 2025-07-25
- Primary outcome
- Changes in blood pressure (BP) (48 hours, from day 1 to day 2. Specifically, it will be assessed before first injection(baseline data) up to 12 hours post last injection.)
- Where
- Norway
- Sponsor (as registered)
- Oslo University Hospital
- Dates
- Start 2015-12 · record updated 2018-01-03
This registry record has not been updated since 2018-01-03, so its "recruiting" status may be out of date.
Olatorepatide 3 open studies, 3 placebo-controlled
Efficacy And Safety of Olatorepatide in Adults With Overweight or Obesity Without Diabetes
- Primary outcome
- Percent change in body weight (From baseline to week 72)
- Where
- Not listed
- Sponsor (as registered)
- Regeneron Pharmaceuticals
- Dates
- Start 2026-11-18 · record updated 2026-10-26
- Primary outcome
- Percent change in total Abscess and inflammatory Nodule (AN) count (From baseline to week 52)
- Where
- United States
- Sponsor (as registered)
- Regeneron Pharmaceuticals
- Dates
- Start 2026-10-29 · record updated 2026-11-10
Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without Diabetes
- Primary outcome
- Occurrence of Treatment-Emergent Adverse Events (TEAEs) (Up to approximately 60 weeks) +2 more
- Where
- United States
- Sponsor (as registered)
- Regeneron Pharmaceuticals
- Dates
- Start 2026-07-28 · record updated 2026-11-06
Pegozafermin 3 open studies, 2 placebo-controlled
- Primary outcome
- Maximum Observed Serum Concentration (Cmax) of Pegozafermin (From predose on Day 1 up to Day 22) +2 more
- Where
- Not listed
- Sponsor (as registered)
- Hoffmann-La Roche
- Dates
- Start 2026-11-05 · record updated 2026-10-19
- Primary outcome
- Proportion of Participants Achieving Fibrosis Regression (Baseline through Month 24) +1 more
- Where
- Argentina, Australia, Belgium, Brazil, Bulgaria, Canada and 19 more
- Sponsor (as registered)
- Hoffmann-La Roche
- Dates
- Start 2024-05-24 · record updated 2026-10-23
- Primary outcome
- Number of Participants With at Least an Improvement of Fibrosis ≥1 Stage Without Worsening of Steatohepatitis at Week 52 (Week 52) +2 more
- Where
- Argentina, Australia, Austria, Belgium, Bulgaria, Canada and 21 more
- Sponsor (as registered)
- Hoffmann-La Roche
- Dates
- Start 2024-03-13 · record updated 2026-10-23
Teverelix 3 open studies, 2 placebo-controlled
- Primary outcome
- Percentage of Participants With Serum Estradiol Maintained Within 20-50 pg/mL for at Least 14 Consecutive Days (From Day 1 to Day 197)
- Where
- Not listed
- Sponsor (as registered)
- Antev Ltd.
- Dates
- Start 2027-02 · record updated 2026-11-03
- Primary outcome
- Percent Change from Baseline in Total Prostate Volume (TPV) at Week 12 (Change from baseline to Week 12)
- Where
- Not listed
- Sponsor (as registered)
- Antev Ltd.
- Dates
- Start 2026-09 · record updated 2026-07-29
- Primary outcome
- To evaluate the efficacy of a dosing regimen of teverelix DP in attaining by Day 29 and sustaining to Day 155 castration rate (22 weeks) +4 more
- Where
- Not listed
- Sponsor (as registered)
- Antev Ltd.
- Dates
- Start 2026-07 · record updated 2026-03-12
VK2735 3 open studies, 3 placebo-controlled
Oral VK2735 for Weight Management in Adults With Type 2 Diabetes Mellitus Phase 3 (SUNRISE 2)
- Primary outcome
- Percent change in body weight for participants with type 2 diabetes mellitus receiving VK2735 orally once daily (68 weeks)
- Where
- United States
- Sponsor (as registered)
- Viking Therapeutics, Inc.
- Dates
- Start 2026-11 · record updated 2026-11-16
Oral VK2735 for Weight Management Phase 3 (SUNRISE 1)
- Primary outcome
- Percentage change in body weight for participants receiving VK2735 orally once daily (68 weeks)
- Where
- United States
- Sponsor (as registered)
- Viking Therapeutics, Inc.
- Dates
- Start 2026-11 · record updated 2026-11-16
A Phase 1 Study of VK2735 in Obese Adults Without Comorbidities
- Primary outcome
- Evaluate the Safety and Tolerability VK2735 (33 weeks)
- Where
- United States
- Sponsor (as registered)
- Viking Therapeutics, Inc.
- Dates
- Start 2025-11-18 · record updated 2026-09-24
Adrenomedullin 2 open studies, 2 placebo-controlled
Selective Activation of the Adrenomedullin Receptors in Migraine
- Primary outcome
- Incidence of migraine attacks (Assessed from baseline to 12 hours post-infusion of adrenomedullin or placebo)
- Where
- Denmark
- Sponsor (as registered)
- Danish Headache Center
- Dates
- Start 2026-03-12 · record updated 2026-08-28
Hypersensitivity to Adrenomedullin in Post-Traumatic Headache
- Primary outcome
- Incidence of headache with migraine-like features (12 hours)
- Where
- Denmark
- Sponsor (as registered)
- Danish Headache Center
- Dates
- Start 2025-08-01 · record updated 2025-07-30
Bimagrumab 2 open studies, 1 placebo-controlled
A Study of Bimagrumab in Participants With HFpEF
- Primary outcome
- Change from Baseline in the Kansas City Cardiomyopathy Questionnaire-Clinical Summary Score (KCCQ-CSS) (Baseline, Week 52)
- Where
- Hungary, Italy, Poland, United States
- Sponsor (as registered)
- Eli Lilly and Company
- Dates
- Start 2026-11 · record updated 2026-11-06
- Primary outcome
- Change in number of kilograms of lean mass by dual-energy x-ray absorptiometry (52 weeks)
- Where
- United States
- Sponsor (as registered)
- Massachusetts General Hospital
- Dates
- Start 2025-11-05 · record updated 2026-03-27
Bofanglutide 2 open studies
BALANCE-DM2 Study of Bofanglutide in Adults With Type 2 Diabetes
- Primary outcome
- Change in Hemoglobin A1c (HbA1c) From Baseline at Week 30 (Baseline to Week 30)
- Where
- Mexico
- Sponsor (as registered)
- Carnot Laboratories
- Dates
- Start 2026-09 · record updated 2026-06-05
- Primary outcome
- Percent Change in Body Weight From Baseline to Week 36 (Baseline to Week 36)
- Where
- Mexico
- Sponsor (as registered)
- Carnot Laboratories
- Dates
- Start 2026-09 · record updated 2026-06-03
BPC-157 2 open studies, 2 placebo-controlled
Impact of BPC-157 on Recovery Following Rotator Cuff Repair Surgery
- Primary outcome
- Shoulder Strength (Baseline, 12 weeks, and 5 months post operatively)
- Where
- United States
- Sponsor (as registered)
- University of Arkansas
- Dates
- Start 2027-01-01 · record updated 2026-09-03
BPC 157 for Acute Hamstring Muscle Strain Repair
- Primary outcome
- Time to return to unrestricted sport participation (days) (8 Weeks) +1 more
- Where
- China
- Sponsor (as registered)
- Hudson Biotech
- Dates
- Start 2026-02-02 · record updated 2026-02-27
C-peptide 2 open studies, 1 placebo-controlled
- Primary outcome
- Frequency and phenotype of Tregs (Within 4 weeks of T1DM diagnosis)
- Where
- France
- Sponsor (as registered)
- Assistance Publique - Hôpitaux de Paris
- Dates
- Start 2025-05-06 · record updated 2025-11-20
Effect of C-peptide on Hypoglycemic Counterregulation
- Primary outcome
- Glucagon (During procedure, up to 2.5 hours)
- Where
- United States
- Sponsor (as registered)
- University of Cincinnati
- Dates
- Start 2024-06-01 · record updated 2026-02-17
Efruxifermin 2 open studies, 2 placebo-controlled
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
- Primary outcome
- Time from randomization to the first significant clinical event including disease progression, liver decompensation events, etc. (5 years) +1 more
- Where
- Argentina, Australia, Belgium, Brazil, Canada, Chile and 17 more
- Sponsor (as registered)
- Akero Therapeutics, Inc
- Dates
- Start 2024-10-04 · record updated 2026-11-12
- Primary outcome
- Cohort 1 Only: Resolution of NASH/MASH and a ≥ 1 stage improvement in fibrosis (52 Weeks) +1 more
- Where
- Argentina, Australia, Canada, France, Germany, India and 12 more
- Sponsor (as registered)
- Akero Therapeutics, Inc
- Dates
- Start 2023-12-01 · record updated 2026-11-06
GLP-1 2 open studies, 1 placebo-controlled
Hypothalamic GLP-1 Response in Healthy Weight and Obesity
- Primary outcome
- Hypothalamic response to glucose ingestion during GLP-1 receptor blockade compared with saline (During the MRI scan on three test days) +1 more
- Where
- Denmark
- Sponsor (as registered)
- University of Copenhagen
- Dates
- Start 2026-10-01 · record updated 2026-11-02
- Primary outcome
- Change in GLP-1 induced nausea intensity (From enrollment to the end of treatment at up to 12 weeks.)
- Where
- Denmark
- Sponsor (as registered)
- University of Copenhagen
- Dates
- Start 2026-05-19 · record updated 2026-07-07
Pentixather 2 open studies
A Safety Study of 212Pb-Pentixather Radioligand Therapy
- Primary outcome
- Determine the recommended phase 2 dose of 212-Lead Pentixather (3 months)
- Where
- United States
- Sponsor (as registered)
- Yusuf Menda
- Dates
- Start 2026-07-01 · record updated 2025-07-08
[90Y]Y-PTT Endoradiotherapy in CNS Lymphoma Patients
- Primary outcome
- Incidence, severity and relationship of (S)AEs (graded in severity according to NCI CTCAE version 5.0) (From screening until including the last follow-up visit. SAEs occuring after the end of the study should only be reported to Pentixapharm if the Investigator considers there is a causal relationship with the study drug.)
- Where
- Germany
- Sponsor (as registered)
- Pentixapharm AG
- Dates
- Start 2023-11-07 · record updated 2026-06-05
Pramlintide 2 open studies, 2 placebo-controlled
Postprandial Regulation of Bone Perfusion in Healthy Individuals
- Primary outcome
- Median Ki in the Femur (90 minutes)
- Where
- Denmark
- Sponsor (as registered)
- University of Copenhagen
- Dates
- Start 2026-07-19 · record updated 2026-07-09
Pancreatic Polypeptide as a Modulator of Amylin- Induced Satiety in Healthy Humans
- Primary outcome
- Food intake (300 to 330 minutes)
- Where
- Denmark
- Sponsor (as registered)
- University Hospital, Gentofte, Copenhagen
- Dates
- Start 2026-04 · record updated 2026-04-01
Retatrutide 2 open studies, 2 placebo-controlled
Effect of Retatrutide Versus Placebo in Participants Who Have Obesity or Are Overweight
- Primary outcome
- Mean percent change in body weight from randomization/baseline to Week 24. (24 weeks)
- Where
- China
- Sponsor (as registered)
- Hudson Biotech
- Dates
- Start 2026-02-15 · record updated 2026-11-12
- Primary outcome
- Time to First Occurrence of Any Component of the Composite Endpoint for Major Adverse Liver Outcomes (MALO) (Baseline up to Study Completion (about 224 weeks))
- Where
- Argentina, Australia, Austria, Belgium, Brazil, Bulgaria and 28 more
- Sponsor (as registered)
- Eli Lilly and Company
- Dates
- Start 2025-10-15 · record updated 2026-10-08
SAR-bisPSMA 2 open studies
- Primary outcome
- Diagnostic performance of 64Cu-SAR-bisPSMA PET to detect regional nodal metastases (Up to 16 weeks)
- Where
- Australia, Puerto Rico, United States
- Sponsor (as registered)
- Clarity Pharmaceuticals Ltd
- Dates
- Start 2023-12-21 · record updated 2026-09-11
- Primary outcome
- Biodistribution of 64Cu-SAR-bisPSMA (48 hours) +11 more
- Where
- United States
- Sponsor (as registered)
- Clarity Pharmaceuticals Ltd
- Dates
- Start 2021-08-11 · record updated 2026-05-06
Apraglutide 1 open study, 1 placebo-controlled
- Primary outcome
- Relative change from baseline in actual weekly PS volume at Week 24. (At Week 24)
- Where
- Argentina, Australia, Austria, Belgium, Brazil, Canada and 16 more
- Sponsor (as registered)
- VectivBio AG
- Dates
- Start 2026-08 · record updated 2026-08-04
Balixafortide 1 open study
Phase I Study of Cosibelimab and Balixafortide in Metastatic Pancreatic Ductal Adenocarcinoma
- Primary outcome
- MTD of Balixafortide (2 Years) +1 more
- Where
- United States
- Sponsor (as registered)
- Arsen Osipov
- Dates
- Start 2026-01 · record updated 2025-11-19
Bradykinin 1 open study
- Primary outcome
- Prognostic Value of Bradykinin degradating enzymes (Association between the activity of kinin-degrading enzymes (ECA, APP, DPP4) measured by enzyme methods, expressed in tertiles, and relapse at 6 months.)
- Where
- France
- Sponsor (as registered)
- University Hospital, Grenoble
- Dates
- Start 2021-10-27 · record updated 2025-02-25
Canvuparatide 1 open study, 1 placebo-controlled
A Study to Investigate Canvuparatide Compared With Placebo in Adult Patients With Hypoparathyroidism
- Primary outcome
- To evaluate the effect of pooled weekly doses of canvuparatide on the proportion of responder patients at week 26. (26 Weeks)
- Where
- Argentina, Canada, United States
- Sponsor (as registered)
- MBX Biosciences
- Dates
- Start 2026-08-26 · record updated 2026-11-17
Catestatin 1 open study, 1 placebo-controlled
Assessment of Serum Catestatin Level in Acne Vulgaris Patients
- Primary outcome
- Evalaute serum level of Catestatin in acne patient (12 weeks) +1 more
- Where
- Egypt
- Sponsor (as registered)
- Aswan University
- Dates
- Start 2025-01-10 · record updated 2025-07-08
CGRP 1 open study, 1 placebo-controlled
Induction of Migraine Attacks With Aura Using Calcitonin Gene-Related Peptide
- Primary outcome
- Incidence of migraine attacks with aura (12 hours)
- Where
- Denmark
- Sponsor (as registered)
- Danish Headache Center
- Dates
- Start 2025-06-27 · record updated 2025-08-06
CNP 1 open study
- Primary outcome
- Safety and Tolerability (Through trial completion, an average of 10 years) +1 more
- Where
- Australia, Austria, Canada, Denmark, France, Germany and 6 more
- Sponsor (as registered)
- Ascendis Pharma Growth Disorders A/S
- Dates
- Start 2023-06-21 · record updated 2026-08-17
DOTA-EB-TATE 1 open study
- Primary outcome
- To determine the optimal dose of 177Lu-DOTA-EB-TATE that is both safe and shows sufficient efficacy for treatment of metastatic HTC based on TITE-BOIN12 design of phase 1/2 clinical trial [1, 2]. (8-12 weeks) +2 more
- Where
- United States
- Sponsor (as registered)
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- Dates
- Start 2026-11-22 · record updated 2026-11-17
ECC5004 1 open study, 1 placebo-controlled
- Primary outcome
- Percent change from baseline to Week 52 in body weight (Week 52) +1 more
- Where
- China, Hong Kong, Malaysia, Philippines, Thailand
- Sponsor (as registered)
- AstraZeneca
- Dates
- Start 2026-08-21 · record updated 2026-11-09
Endothelin-1 1 open study
Prenatal Aspirin and Postpartum Vascular Function
- Primary outcome
- microvascular endothelial function (at the study visit, an average of 4 hours) +1 more
- Where
- United States
- Sponsor (as registered)
- Anna Stanhewicz, PhD
- Dates
- Start 2023-01-03 · record updated 2025-05-31
Gastrin 1 open study
Improving Islet Transplantation Outcomes With Gastrin for Type I Diabetes
- Primary outcome
- Proportion of subjects who are insulin independent, free from severe hypoglycemia and have HbA1c less than or equal to 6.5% ("complete response") (1 year post transplant (6 months after second course of Gastrin))
- Where
- United States
- Sponsor (as registered)
- City of Hope Medical Center
- Dates
- Start 2019-05-29 · record updated 2026-10-15
GHK-Cu 1 open study, 1 placebo-controlled
Topical GHK-Cu Gel for Acute Skin Wound Healing
- Primary outcome
- Time to complete re-epithelialization (days) of each wound, defined as 100% epithelial coverage without drainage, confirmed by blinded clinical assessment and standardized photography. (21 Days)
- Where
- China
- Sponsor (as registered)
- Hudson Biotech
- Dates
- Start 2026-02-02 · record updated 2026-02-27
Glepaglutide 1 open study, 1 placebo-controlled
Efficacy And Safety Evaluation of Glepaglutide in Treatment of SBS
- Primary outcome
- Change in weekly Parenteral Support (PS) volume (Baseline to Week 24)
- Where
- Austria, Belgium, Denmark, Finland, France, Germany and 8 more
- Sponsor (as registered)
- Zealand Pharma
- Dates
- Start 2026-02-11 · record updated 2026-09-29
GLP-2 1 open study, 1 placebo-controlled
Postprandial Regulation of Bone Perfusion in Healthy Individuals
- Primary outcome
- Median Ki in the Femur (90 minutes)
- Where
- Denmark
- Sponsor (as registered)
- University of Copenhagen
- Dates
- Start 2026-07-19 · record updated 2026-07-09
Gonadorelin 1 open study, 1 placebo-controlled
GnRH Therapy on Cognition in Down Syndrome
- Primary outcome
- Cognition (Baseline to end of treatment (Week 24))
- Where
- Switzerland
- Sponsor (as registered)
- Nelly Pitteloud
- Dates
- Start 2020-08-27 · record updated 2024-02-12
This registry record has not been updated since 2024-02-12, so its "recruiting" status may be out of date.
HM15275 1 open study, 1 placebo-controlled
Study to Evaluate HM15275 in Subjects With Type 2 Diabetes Mellitus
- Primary outcome
- Change in Glycated Hemoglobin (HbA1c) (Up to 41 weeks)
- Where
- United States
- Sponsor (as registered)
- Hanmi Pharmaceutical Company Limited
- Dates
- Start 2026-05-18 · record updated 2026-10-19
Insulin detemir 1 open study
- Primary outcome
- Neonatal Hypoglycemia (Within the first 24 hours of life) +1 more
- Where
- United States
- Sponsor (as registered)
- University of California, Los Angeles
- Dates
- Start 2022-02-01 · record updated 2023-09-26
This registry record has not been updated since 2023-09-26, so its "recruiting" status may be out of date.
LSALT peptide 1 open study, 1 placebo-controlled
- Primary outcome
- To evaluate the percentage of subjects with AKI within 7 days following on-pump cardiac surgery defined by the KDIGO (Kidney Disease: Improving Global Outcomes) criteria (7 days)
- Where
- Canada, Turkey (Türkiye)
- Sponsor (as registered)
- Arch Biopartners Inc.
- Dates
- Start 2024-03-08 · record updated 2026-06-12
Melanotan II 1 open study, 1 placebo-controlled
- Primary outcome
- Change from baseline in Vitiligo Area Scoring Index (VASI) total score (24 Weeks)
- Where
- China
- Sponsor (as registered)
- Hudson Biotech
- Dates
- Start 2026-02-02 · record updated 2026-11-12
MK-677 1 open study, 1 placebo-controlled
Phase 3 Study of LUM-201 in Children With Growth Hormone Deficiency
- Primary outcome
- AHV after 12 months on LUM-201 compared to placebo (Day 1 to Month 12)
- Where
- Argentina, Australia, Chile, India, New Zealand, Thailand and 2 more
- Sponsor (as registered)
- Lumos Pharma
- Dates
- Start 2026-05-20 · record updated 2026-10-19
MOTS-c 1 open study, 1 placebo-controlled
MOTS-c for Improving Insulin Sensitivity in Adults With Prediabetes and Overweight/Obesity
- Primary outcome
- Change from baseline in OGTT-derived insulin sensitivity (Matsuda Index) (12 Weeks) +1 more
- Where
- China
- Sponsor (as registered)
- Hudson Biotech
- Dates
- Start 2026-02-02 · record updated 2026-04-01
Neuropeptide Y 1 open study
Sympathetic Transduction in Obesity-associated Hypertension (OB-HTN)
- Primary outcome
- Blood flow measured by doppler ultrasound (Acutely on the day of study) +1 more
- Where
- United States
- Sponsor (as registered)
- University of Texas Southwestern Medical Center
- Dates
- Start 2021-07-18 · record updated 2026-09-03
PACAP 1 open study, 1 placebo-controlled
Induction of Migraine Attacks With Aura Using Pituitary Adenylate Cyclase Activating Polypeptide-38
- Primary outcome
- Incidence of migraine attacks with aura (12 hours)
- Where
- Not listed
- Sponsor (as registered)
- Danish Headache Center
- Dates
- Start 2026-02-01 · record updated 2026-01-15
Pancreatic polypeptide 1 open study, 1 placebo-controlled
Pancreatic Polypeptide as a Modulator of Amylin- Induced Satiety in Healthy Humans
- Primary outcome
- Food intake (300 to 330 minutes)
- Where
- Denmark
- Sponsor (as registered)
- University Hospital, Gentofte, Copenhagen
- Dates
- Start 2026-04 · record updated 2026-04-01
Pemvidutide 1 open study, 1 placebo-controlled
Phase 3 Study of the Efficacy, Safety, and Clinical Outcomes of Pemvidutide in MASH
- Primary outcome
- Clinical Outcome Event (Baseline through end of study (approximately Month 60)) +2 more
- Where
- Puerto Rico, United States
- Sponsor (as registered)
- Altimmune, Inc.
- Dates
- Start 2026-07-30 · record updated 2026-11-17
Sonefpeglutide 1 open study, 1 placebo-controlled
Phase 2 Study to Assess the Safety, PK, and PD of Sonefpeglutide (HM15912) in SBS-IF Subjects
- Primary outcome
- Incidence of adverse events (AEs) (for 24 weeks)
- Where
- Belgium, Denmark, France, Germany, Poland, South Korea and 2 more
- Sponsor (as registered)
- Hanmi Pharmaceutical Company Limited
- Dates
- Start 2022-03-03 · record updated 2026-08-12
Substance P 1 open study, 1 placebo-controlled
Substance P-Induced Migraine Attacks Without Aura
- Primary outcome
- Incidence of migraine attacks without aura (12 hours)
- Where
- Denmark
- Sponsor (as registered)
- Danish Headache Center
- Dates
- Start 2025-05-13 · record updated 2025-06-05
TB-500 1 open study, 1 placebo-controlled
TB-500 (Thymosin Beta 4 17-23 Fragment) for Cardiovascular Biomarkers in Stable ASCVD
- Primary outcome
- incidence of treatment-emergent adverse events (TEAEs) (12 weeks) +1 more
- Where
- China
- Sponsor (as registered)
- Hudson Biotech
- Dates
- Start 2026-02-05 · record updated 2026-11-12
VMT-α-NET 1 open study
Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors
- Primary outcome
- Number of participants with dose-limiting toxicities (DLTs) after the first administration of [212Pb]VMT-α-NET (Incidence and severity of DLTs during the first 42 days of study treatment will be assessed.) +3 more
- Where
- United States
- Sponsor (as registered)
- Perspective Therapeutics
- Dates
- Start 2023-09-27 · record updated 2026-10-13
Zadavotide Guraxetan 1 open study
- Primary outcome
- Radiographic Progression-Free Survival (rPFS) (From randomization until first radiographic progression per RECIST 1.1/PCWG3 by BICR, or death from any cause, whichever occurs first (up to approximately 33 months)) +1 more
- Where
- Australia, Austria, Belgium, Brazil, Canada, China and 18 more
- Sponsor (as registered)
- AstraZeneca
- Dates
- Start 2026-05-04 · record updated 2026-10-19
Zelenectide Pevedotin 1 open study
- Primary outcome
- Monitor safety for participants receiving a Bicycle investigational product (Up to 48 months)
- Where
- Not listed
- Sponsor (as registered)
- BicycleTx Limited
- Dates
- Start 2026-08-01 · record updated 2026-07-02
Zelpultide alfa 1 open study, 1 placebo-controlled
- Primary outcome
- Incidence of grade 2 or grade 3 Bronchopulmonary Dysplasia (BPD) or death (Week 36 Post Menstrual Age (PMA))
- Where
- Argentina, Belgium, Czechia, France, Germany, Israel and 4 more
- Sponsor (as registered)
- Airway Therapeutics, Inc.
- Dates
- Start 2025-02-03 · record updated 2026-11-17
Approved abroad, or sold as a supplement (28)
Not FDA-approved, but approved in another country or sold as a supplement or diagnostic. Large programs show their 12 newest studies, with a link to the full list.
Melatonin 77 open studies, 48 placebo-controlled
- Primary outcome
- Difference in sleep-diary derived total sleep time after 13 weeks of treatment (At Day 0 and day 92)
- Where
- France
- Sponsor (as registered)
- University Hospital, Strasbourg, France
- Dates
- Start 2027-01-01 · record updated 2026-02-18
- Primary outcome
- Change in Left Ventricular Ejection Fraction (LVEF) (Baseline and 3 months) +2 more
- Where
- Not listed
- Sponsor (as registered)
- Tanta University
- Dates
- Start 2026-12-20 · record updated 2026-01-12
Adjunctive Melatonin Gel With MINST on GCF Galectin-3 and IL-1 in Stage III-IV Periodontitis
- Primary outcome
- Clinical Attachment Level (CAL) (Baseline, 1 month, and 2 months after treatment) +7 more
- Where
- Not listed
- Sponsor (as registered)
- Badr University
- Dates
- Start 2026-11-30 · record updated 2026-11-09
Melatonin in Posterior Mandible Extraction Socket
- Primary outcome
- the dimensional change in vertical alveolar bone height (12 weeks)
- Where
- Not listed
- Sponsor (as registered)
- Cairo University
- Dates
- Start 2026-11-15 · record updated 2026-11-06
- Primary outcome
- Change from Baseline in Patient-Reported Outcomes Measurement Information System (PROMIS) Pediatric Sleep Disturbance T-Score (Baseline and weekly through Week 4 of the product or placebo use period)
- Where
- United States
- Sponsor (as registered)
- Olly, PBC
- Dates
- Start 2026-11-09 · record updated 2026-11-12
Oral Melatonin as Adjunctive Therapy in Adults With Atopic Dermatitis
- Primary outcome
- Change in SCORAD Score From Baseline to Week 4 (Baseline to Week 4)
- Where
- Not listed
- Sponsor (as registered)
- Can Tho University of Medicine and Pharmacy
- Dates
- Start 2026-10-10 · record updated 2026-09-25
Melatonin and Immunonutrition for Pain Relief in Fibromyalgia
- Primary outcome
- VAS pain (5 weeks) +5 more
- Where
- Greece
- Sponsor (as registered)
- University of Thessaly
- Dates
- Start 2026-10 · record updated 2026-10-07
Locally Delivered Melatonin Gel in Management of Stage II Grade B Periodontitis
- Primary outcome
- Change in clinical attachment loss (Baseline and 8 weeks)
- Where
- Egypt
- Sponsor (as registered)
- Alexandria University
- Dates
- Start 2026-09-10 · record updated 2026-09-10
Effects of Melatonin on Sleep Architecture of Critically Ill Patients in the ICU
- Primary outcome
- Sleep Efficiency as measured by total sleep time over time in bed (From enrollment to the end of 48 hours of the last subject's participation in the study) +3 more
- Where
- Not listed
- Sponsor (as registered)
- Rutgers, The State University of New Jersey
- Dates
- Start 2026-09-01 · record updated 2026-07-13
- Primary outcome
- Change from baseline in mean Total Sleep Time (TST) measured by Sleep Diary (Baseline (Day-14 to Day 0) and end of treatment (Day 78 to Day 93))
- Where
- France
- Sponsor (as registered)
- Assistance Publique Hopitaux De Marseille
- Dates
- Start 2026-09-01 · record updated 2026-05-08
- Primary outcome
- Sleep Quality (14 days)
- Where
- Egypt
- Sponsor (as registered)
- Benha University
- Dates
- Start 2026-08-04 · record updated 2026-07-29
Efficacy of CBT-I With Adjuvant Melatonin in Older Adults Chronic Insomnia
- Primary outcome
- Insomnia Symptoms - Insomnia Severity Index (Baseline, Mid-session (Week 2 of the intervention), Post-Treatment (one-week after treatment conclusion) for all participants, and at Post-Treatment 3-month and Post-Treatment 6-month for participants in the treatment groups.)
- Where
- Hong Kong
- Sponsor (as registered)
- The University of Hong Kong
- Dates
- Start 2026-08-01 · record updated 2026-08-21
Showing the 12 newest of 77. See all on ClinicalTrials.gov.
Mazdutide 21 open studies, 16 placebo-controlled
Efficacy, Safety and Cardiovascular Protection of Mazdutide in Type 1 Diabetes
- Primary outcome
- Proportion of the participants achieving time in range (TIR)>70 and time below range (TBR)<4% (TIMES-EFFICACY) (From baseline to 16 weeks) +1 more
- Where
- Not listed
- Sponsor (as registered)
- Peking University People's Hospital
- Dates
- Start 2027-01-01 · record updated 2026-11-09
Efficacy of Mazdutide on Fatty Pancreas
- Primary outcome
- Percentage change in Intrapancreatic Fat Deposition (IPFD) from baseline (From baseline to Week 48)
- Where
- China
- Sponsor (as registered)
- Tongji Hospital
- Dates
- Start 2026-11-15 · record updated 2026-09-22
QUARTET-DKD: Quadruple Therapy for Type 2 Diabetic Nephropathy
- Primary outcome
- Relative Change From Baseline in Urine Albumin-to-Creatinine Ratio (UACR) at Month 6 (Baseline and Month 6)
- Where
- China
- Sponsor (as registered)
- Huijie Zhang
- Dates
- Start 2026-11-03 · record updated 2026-11-10
Mazdutide Plus LNG-IUS for Fertility-Sparing Treatment of AEH or Early Endometrial Cancer
- Primary outcome
- Complete response rate of endometrial lesions at 24 week (At 24 weeks after randomization)
- Where
- China
- Sponsor (as registered)
- Tongji Hospital
- Dates
- Start 2026-11-01 · record updated 2026-08-24
Mazdutide for Reducing Atrial Fibrillation Recurrence After Catheter Ablation in Obese Patients
- Primary outcome
- Recurrence of atrial arrhythmias at 12 months after a single ablation procedure without the use of any Class I/III antiarrhythmic drugs (AADs). (From enrollment to the end of treatment at 52 weeks) +1 more
- Where
- China
- Sponsor (as registered)
- Beijing Anzhen Hospital
- Dates
- Start 2026-10-25 · record updated 2026-10-27
A Study of HRS-4729 Injection in Participants With Type 2 Diabetes
- Primary outcome
- Change From Baseline in HbA1c (Baseline, Week 28)
- Where
- China
- Sponsor (as registered)
- Fujian Shengdi Pharmaceutical Co., Ltd.
- Dates
- Start 2026-10 · record updated 2026-09-28
- Primary outcome
- Proportion of Participants Achieving Normal Glucose Regulation (NGR) at Week 44 (Baseline, 44 weeks)
- Where
- China
- Sponsor (as registered)
- Yanbing Li
- Dates
- Start 2026-09-30 · record updated 2026-08-17
Mazdutide for Weight Management and Gout in Adults With Obesity
- Primary outcome
- Annualized Flare Rate (AFR) (Baseline to Week 52;Unit of Measure: Flares per person-year)
- Where
- Not listed
- Sponsor (as registered)
- Hongwei Jiang
- Dates
- Start 2026-09-15 · record updated 2026-09-17
- Primary outcome
- Change in total non-calcified plaque volume (NCPV) by CCTA from baseline to 52 weeks (Baseline and 52 weeks)
- Where
- China
- Sponsor (as registered)
- China National Center for Cardiovascular Diseases
- Dates
- Start 2026-09-14 · record updated 2026-10-13
Body-weight Reduction Effect on Portal Hypertension in Compensated Cirrhosis
- Primary outcome
- Percentage Change in Hepatic Venous Pressure Gradient (HVPG) from Baseline (Baseline (screening, Day -14 to -1) to Week 16 (End of Treatment, Day 112 ± 3 days))
- Where
- Not listed
- Sponsor (as registered)
- The Second Affiliated Hospital of Chongqing Medical University
- Dates
- Start 2026-09-01 · record updated 2026-09-01
Pre-hepatectomy Rehabilitation in Obese MASLD-Complicated Living Liver Donors With Mazdutide (PRIME)
- Primary outcome
- Proportion of Participants Achieving Resolution of MASLD Without Worsening of Liver Fibrosis (ROM) (From randomization (Week 0) to Week 12)
- Where
- China
- Sponsor (as registered)
- West China Hospital
- Dates
- Start 2026-09-01 · record updated 2026-09-23
- Primary outcome
- Proportion of Participants Achieving Normal Glucose Regulation (NGR) at Week 24 (Week 24)
- Where
- China
- Sponsor (as registered)
- Shandong Provincial Hospital
- Dates
- Start 2026-07 · record updated 2026-06-17
Showing the 12 newest of 21. See all on ClinicalTrials.gov.
Carbetocin 12 open studies, 5 placebo-controlled
The Efficacy of Carbitocin in Reduction of Blood Loss During Myomectomy
- Primary outcome
- Haemoglobin Change (24months)
- Where
- Not listed
- Sponsor (as registered)
- Alex Ekwueme Federal University Teaching Hospital
- Dates
- Start 2026-08-15 · record updated 2026-07-23
- Primary outcome
- Additional Uterotonic Requirement Within 24 Hours (Within 24 hours of delivery)
- Where
- Saudi Arabia
- Sponsor (as registered)
- Mansoura University
- Dates
- Start 2026-08-08 · record updated 2026-10-09
Carbetocin Uterotonic Treatment in Twin Pregnancies for Prevention of Postpartum Hemorrhage
- Primary outcome
- Change in maternal hemoglobin level from baseline to postpartum (The most recent hemoglobin measurement taken within 30 days prior to delivery to the day after delivery.)
- Where
- Israel
- Sponsor (as registered)
- Sheba Medical Center
- Dates
- Start 2026-05-05 · record updated 2026-05-08
Carbetocin vs Misoprostol for Postpartum Hemorrhage Prevention
- Primary outcome
- Postpartum hemorrhage (PPH) (Within 24 hours after delivery) +1 more
- Where
- Not listed
- Sponsor (as registered)
- Western Galilee Hospital-Nahariya
- Dates
- Start 2026-01-31 · record updated 2026-01-20
Ergometrine Versus Carbetocin to Decrease Blood Loss in Myomectomy
- Primary outcome
- Estimated Intraoperative and Postoperative Blood Loss (From the start of surgery until removal of the intraperitoneal drain (up to 48 hours postoperatively))
- Where
- Egypt
- Sponsor (as registered)
- Cairo University
- Dates
- Start 2026-01-18 · record updated 2026-02-05
- Primary outcome
- Amount of blood loss (during and up to 24 hours after cesarean section)
- Where
- Not listed
- Sponsor (as registered)
- Cairo University
- Dates
- Start 2026-01-01 · record updated 2026-01-06
- Primary outcome
- Uterine Tone 10 minutes (10 minutes)
- Where
- Canada
- Sponsor (as registered)
- Samuel Lunenfeld Research Institute, Mount Sinai Hospital
- Dates
- Start 2025-12-01 · record updated 2026-04-01
Effect of Extracellular Calcium on Carbetocin Mediated Contractility in Human Myometrium
- Primary outcome
- Motility index (4 hours)
- Where
- Canada
- Sponsor (as registered)
- Samuel Lunenfeld Research Institute, Mount Sinai Hospital
- Dates
- Start 2025-09-15 · record updated 2026-11-13
Cardiac Changes After Effective Dose Carbetocin for Elective Caesarian Section
- Primary outcome
- Patient reported symptoms (within 5 minutes of study drug administration)
- Where
- Canada
- Sponsor (as registered)
- Jordan Leitch
- Dates
- Start 2025-08-01 · record updated 2025-04-27
- Primary outcome
- Proportion of parturients requiring additional uterotonic agents intraoperatively (90 minutes)
- Where
- Canada
- Sponsor (as registered)
- Samuel Lunenfeld Research Institute, Mount Sinai Hospital
- Dates
- Start 2025-01-14 · record updated 2026-04-01
- Primary outcome
- Motility index (4 hours)
- Where
- Canada
- Sponsor (as registered)
- Samuel Lunenfeld Research Institute, Mount Sinai Hospital
- Dates
- Start 2024-04-04 · record updated 2026-04-06
- Primary outcome
- To measure the volume of intraoperative blood loss in each group without using haemostatic tourniquets (12 hours)
- Where
- Egypt
- Sponsor (as registered)
- Wael Elbanna Clinic
- Dates
- Start 2021-12-30 · record updated 2022-03-04
This registry record has not been updated since 2022-03-04, so its "recruiting" status may be out of date.
Recombinant Human Endostatin 8 open studies
- Primary outcome
- Overall Survival (OS) (From enrollment to death from any cause, assessed up to 60 months.)
- Where
- Not listed
- Sponsor (as registered)
- Jiangmen Central Hospital
- Dates
- Start 2026-09-01 · record updated 2026-10-01
Platinum-Free Regimen in Nasopharyngeal Carcinoma
- Primary outcome
- Recurrence-free survival (Time from enrollment to the first occurrence of disease recurrence (including distant metastasis or locoregional recurrence) or death from any cause, whichever occurs first, assessed up to 60 months.)
- Where
- China
- Sponsor (as registered)
- Zhejiang Cancer Hospital
- Dates
- Start 2026-09-01 · record updated 2026-08-31
Envafolimab Combined With Chemoradiotherapy and Recombinant Human Endostatin for LA-NPC.
- Primary outcome
- Complete Response Rate (CRR) after Induction Therapy (From enrollment to the end of induction therapy at 12 weeks)
- Where
- China
- Sponsor (as registered)
- Chongqing University Cancer Hospital
- Dates
- Start 2026-02-09 · record updated 2026-02-18
Endostatin Adenovirus With Checkpoint Inhibitor in Advanced Head and Neck or Esophageal Cancer
- Primary outcome
- Incidence of treatment-related adverse effects (TRAEs) (Through study completion, an average of 1.5 year) +1 more
- Where
- China
- Sponsor (as registered)
- Sichuan University
- Dates
- Start 2025-09-01 · record updated 2025-09-04
Perioperative Toripalimab and Endostatin for Stage II Melanoma: A Phase II Trial
- Primary outcome
- 2-year recurrence-free survival rate (2-year RFS rate) (From enrollment to the end of the 2nd year of follow-up)
- Where
- China
- Sponsor (as registered)
- Fudan University
- Dates
- Start 2025-01-01 · record updated 2025-05-11
- Primary outcome
- Progression-Free Survival (PFS) (From the initiation of treatment (Day 1) until the first occurrence of disease progression, death, or the end of the study, whichever came first,up to approximately 5 years.)
- Where
- Not listed
- Sponsor (as registered)
- Jian-Guo Zhou, MD, PhD
- Dates
- Start 2024-12-17 · record updated 2024-12-27
GEP Combined With Radiotherapy in Non-locally Treatable Recurrent NPC
- Primary outcome
- 3 year OS rate (3 year)
- Where
- Not listed
- Sponsor (as registered)
- Zhejiang Cancer Hospital
- Dates
- Start 2024-09-30 · record updated 2024-09-25
This registry record has not been updated since 2024-09-25, so its "not yet recruiting" status may be out of date.
- Primary outcome
- Surgical resection rate (From enrollment to the end of surgery)
- Where
- China
- Sponsor (as registered)
- Hua Zhang
- Dates
- Start 2024-08-27 · record updated 2025-07-15
Cerebrolysin 7 open studies, 4 placebo-controlled
Combined Acupuncture-Based Therapy for Rehabilitation After Ischemic Stroke
- Primary outcome
- Change in Fugl-Meyer Assessment score for motor function in post-acute stroke patients (Baseline (Day 0) to Day 15 and Day 30)
- Where
- Vietnam
- Sponsor (as registered)
- National Hospital of Acupuncture, Vietnam
- Dates
- Start 2026-12-01 · record updated 2026-09-29
Cerebrolysin After Reperfusion in Extended-window EndoVascular Thrombectomy
- Primary outcome
- Final Infarct Volume on Diffusion-Weighted MRI (Day 7 to Day 10 after stroke onset)
- Where
- Not listed
- Sponsor (as registered)
- Chang Gung Memorial Hospital
- Dates
- Start 2026-09-01 · record updated 2026-08-11
- Primary outcome
- Efficacy Outcome (90 days from stroke onset) +1 more
- Where
- Not listed
- Sponsor (as registered)
- Cardinal Stefan Wyszynski University
- Dates
- Start 2025-10-01 · record updated 2025-03-28
Cerebrolysin in Early Stroke Rehabilitation - Tertiary Study
- Primary outcome
- 90-day Action Research Arm Test (ARAT) Score change (90 days post-stroke)
- Where
- Slovenia
- Sponsor (as registered)
- University Medical Centre Ljubljana
- Dates
- Start 2025-06-13 · record updated 2025-07-09
Cerebrolysin in Critically Ill Patients With Delirium
- Primary outcome
- CAM-ICU test (seven days) +1 more
- Where
- Poland
- Sponsor (as registered)
- Medical University of Lublin
- Dates
- Start 2024-01-01 · record updated 2024-12-31
Efficacy of Prednisolone Versus Cerebrolysin in the Treatment of Bell's Palsy
- Primary outcome
- change in scores of the house Brackman grading system HB (at baseline, after 1 week, after 3 week) +1 more
- Where
- Egypt
- Sponsor (as registered)
- October 6 University
- Dates
- Start 2023-08-24 · record updated 2025-07-31
Efficacy and Safety of Cerebrolysin on Prolonged Disorders of Consciousness
- Primary outcome
- Coma Recovery Scale - revised (2 days after randomization) +3 more
- Where
- South Korea
- Sponsor (as registered)
- Konkuk University Medical Center
- Dates
- Start 2023-06-01 · record updated 2026-05-11
Ecnoglutide 7 open studies, 7 placebo-controlled
- Primary outcome
- Percentage Change in Body Weight (Baseline, week 24)
- Where
- China
- Sponsor (as registered)
- Hangzhou Sciwind Biosciences Co., Ltd.
- Dates
- Start 2026-11-10 · record updated 2026-11-10
A Study of Ecnoglutide Injection in Overweight or Obese Chinese Adolescents
- Primary outcome
- Percent change in Body Mass Index (BMI) (Baseline, week 40)
- Where
- China
- Sponsor (as registered)
- Hangzhou Sciwind Biosciences Co., Ltd.
- Dates
- Start 2026-10-31 · record updated 2026-09-23
A Study of Econoglutide Injection in Obese Participants With Knee Osteoarthritis (KOA)
- Primary outcome
- Change in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score (Baseline, week 68) +1 more
- Where
- China
- Sponsor (as registered)
- Hangzhou Sciwind Biosciences Co., Ltd.
- Dates
- Start 2026-08-03 · record updated 2026-08-31
- Primary outcome
- Number of Participants with Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) (Screening up to End of Study (Arm 1: Day 29, Arm 2: Week 10, and Arm 3: Week 20)) +3 more
- Where
- Australia
- Sponsor (as registered)
- Verdiva Bio Dev Limited
- Dates
- Start 2026-07-06 · record updated 2026-10-13
- Primary outcome
- Change from baseline in Apnea-Hypopnea Index (AHI) (at week 48)
- Where
- China
- Sponsor (as registered)
- Hangzhou Sciwind Biosciences Co., Ltd.
- Dates
- Start 2026-03-02 · record updated 2026-08-28
- Primary outcome
- Change from baseline in Apnea-Hypopnea Index (AHI) (at week 48)
- Where
- China
- Sponsor (as registered)
- Hangzhou Sciwind Biosciences Co., Ltd.
- Dates
- Start 2026-02-09 · record updated 2026-08-28
- Primary outcome
- The incidence and severity of adverse events (up to day 204)
- Where
- China
- Sponsor (as registered)
- Hangzhou Sciwind Biosciences Co., Ltd.
- Dates
- Start 2025-11-18 · record updated 2026-11-16
Follitropin delta 6 open studies
Embryo QUAlity in Ovarian Stimulation With hMG.
- Primary outcome
- Good quality blastocysts (From Day 5 to Day 7 after insemination)
- Where
- Spain
- Sponsor (as registered)
- Fundacion Dexeus
- Dates
- Start 2026-09 · record updated 2026-07-08
- Primary outcome
- Percentage of cycles with two mature follicles (total of two ovaries) at the stage of triggering ovulation (up to 9 months)
- Where
- France
- Sponsor (as registered)
- Centre Hospitalier Intercommunal Creteil
- Dates
- Start 2025-12-17 · record updated 2026-04-08
Menopur And Rekovelle Combination Study Version 2.0
- Primary outcome
- number of good quality (>3BB) or utilizable blastocysts per treatment cycle at day 5 or 6 of embryo culture (5 to 6 days after egg retrieval (up to 1 to 2 months after enrollment))
- Where
- Canada
- Sponsor (as registered)
- Clinique Ovo
- Dates
- Start 2025-07-04 · record updated 2025-07-31
Ovulation Trigger Strategies in Low Ovarian Reserve (TRIGGERBEST)
- Primary outcome
- Number of mature oocytes (MII) (During the oocyte retrieval procedure)
- Where
- Spain
- Sponsor (as registered)
- Fundación para la Investigación del Hospital Clínico de Valencia
- Dates
- Start 2024-09-17 · record updated 2026-09-11
INtensity of OVarian Stimualtion and Euploid Embryos
- Primary outcome
- Number of euploid embryos (Trough study completion, an average of 20-30 days.)
- Where
- Spain
- Sponsor (as registered)
- Fundación Santiago Dexeus Font
- Dates
- Start 2023-12-12 · record updated 2026-09-08
Real-world Evidence on Follitropin Delta Individual Dosing
- Primary outcome
- Ovarian response (2021-2022)
- Where
- Germany
- Sponsor (as registered)
- University of Luebeck
- Dates
- Start 2021-12-08 · record updated 2025-03-30
Efsubaglutide alfa 5 open studies, 4 placebo-controlled
Phase Ib Study of Efsubaglutide Alfa Injection in Obese Adolescents
- Primary outcome
- Safety and tolerability: incidence of TEAEs, SAEs, and AESI (Throughout the study (up to Week 18)) +1 more
- Where
- China
- Sponsor (as registered)
- Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.
- Dates
- Start 2026-07-16 · record updated 2026-07-30
A Bridging Study of Efsubaglutide Alfa in Healthy Adults in Brazil
- Primary outcome
- Maximum Observed Plasma Concentration (Cmax) of YN-011 (Predose through Day 29) +4 more
- Where
- Brazil
- Sponsor (as registered)
- Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.
- Dates
- Start 2026-06-01 · record updated 2026-04-08
Evaluating Anti-Obesity Medications 6 Months After Metabolic Surgery
- Primary outcome
- Change in %TWL from baseline to endpoint (24 weeks from enrollment)
- Where
- China
- Sponsor (as registered)
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
- Dates
- Start 2025-09-16 · record updated 2026-01-27
The Efficacy and Safety of Efsubaglutide Alfa in Overweight/Obesity(SPARKLE)
- Primary outcome
- Percentage change (%) of body weight from baseline after subcutaneous administration of YN-011 for 22 weeks (22 weeks)
- Where
- Australia
- Sponsor (as registered)
- Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.
- Dates
- Start 2025-08-25 · record updated 2025-12-02
Efficacy and Safety of Efsubaglutide Alfa Injection 3 Mg Q2W in T2D Patients
- Primary outcome
- Time in range (TIR) (6-8 weeks)
- Where
- Not listed
- Sponsor (as registered)
- Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.
- Dates
- Start 2025-07-30 · record updated 2025-03-28
Teicoplanin 5 open studies
Early Discontinuation of Antibiotics in Paediatric High-risk Febrile Neutropenia
- Primary outcome
- Composite rate of adverse outcomes attributable to invasive or clinically significant bacterial infection (Day 0 (randomization) to Day 28)
- Where
- Spain
- Sponsor (as registered)
- Hospital Universitari Vall d'Hebron Research Institute
- Dates
- Start 2026-06-01 · record updated 2026-05-15
- Primary outcome
- Proportion of ACLF patients with nosocomial infection by carbapenem resistant organisms showing clinical response at the end of treatment. (Day 3)
- Where
- India
- Sponsor (as registered)
- Institute of Liver and Biliary Sciences, India
- Dates
- Start 2025-05-22 · record updated 2026-11-09
- Primary outcome
- use population pharmacokinetics model to find out the risk factors (From enrollment to the end of treatment at last 2 weeks)
- Where
- Not listed
- Sponsor (as registered)
- National Taiwan University Hospital
- Dates
- Start 2025-01-01 · record updated 2024-11-05
This registry record has not been updated since 2024-11-05, so its "not yet recruiting" status may be out of date.
Pediatric Antibiotic Dosing in Extracorporal Membrane Oxygenation (PADECMO)
- Primary outcome
- Amoxicillin: probability of target attainment with target the % of time during which the unbound drug concentration remains above the Minimal Inhibitory Concentration (fT>MIC) of the micro-organism (up to 1 month) +16 more
- Where
- Belgium
- Sponsor (as registered)
- University Hospital, Ghent
- Dates
- Start 2016-08-19 · record updated 2026-09-21
PRF With Topical Antibiotics or Antiseptics in Chronical Wounds Version 1.4
- Primary outcome
- reduction in wound area (day 56)
- Where
- Austria
- Sponsor (as registered)
- Medical University of Vienna
- Dates
- Start 2014-06 · record updated 2022-04-07
This registry record has not been updated since 2022-04-07, so its "recruiting" status may be out of date.
Collagen Peptides 4 open studies, 4 placebo-controlled
Effects of Different Collagen Formulations on Knee Osteoarthritis
- Primary outcome
- Change in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Total Score (Baseline (Week 0) and End of Intervention (Week 8))
- Where
- Turkey (Türkiye)
- Sponsor (as registered)
- Cihangir Türemiş
- Dates
- Start 2026-10-01 · record updated 2026-09-02
Dietary Supplements and Middle Aged Women (Collagen & Omega)
- Primary outcome
- Joint pain under 3 conditions as measured by a 100 mm visual analogue scale (VAS) (8 weeks)
- Where
- United Kingdom
- Sponsor (as registered)
- Loughborough University
- Dates
- Start 2026-05-01 · record updated 2026-08-03
Collagen Peptides and Cellular Aging
- Primary outcome
- Telomere length (Baseline and after supplementation (24 weeks)) +3 more
- Where
- Austria
- Sponsor (as registered)
- University of Vienna
- Dates
- Start 2026-04-22 · record updated 2026-05-05
- Primary outcome
- Intestinal permeability (Day 42 to Day 45)
- Where
- Ireland
- Sponsor (as registered)
- Rousselot BVBA
- Dates
- Start 2026-03-25 · record updated 2026-05-27
Somatostatin 4 open studies
- Primary outcome
- Renal function recovery (6 weeks)
- Where
- China
- Sponsor (as registered)
- General Hospital of Shenyang Military Region
- Dates
- Start 2026-09-25 · record updated 2026-08-27
- Primary outcome
- Decrease in portal pressure by 20% from the baseline (Baseline (before bolus drug administration) 5 minutes after bolus drug administration Immediately after completion of the portal vein anastomosis Immediately after completion of the hepatic artery anastomosis)
- Where
- Turkey (Türkiye)
- Sponsor (as registered)
- Istanbul Medipol University Hospital
- Dates
- Start 2025-12-29 · record updated 2026-04-29
- Primary outcome
- Grade C Anastomotic Leakage Within 1 Month After Surgery (Within 1 month after surgery)
- Where
- China
- Sponsor (as registered)
- Tongji Hospital
- Dates
- Start 2025-11-17 · record updated 2026-05-26
Regional Lipolysis and Adipocyte Lipolysis Protein Stimulation
- Primary outcome
- Free Fatty Acid (FFA) release from femoral, splanchnic and upper body subcutaneous adipose tissue (approximately 3.5 hours) +1 more
- Where
- United States
- Sponsor (as registered)
- Mayo Clinic
- Dates
- Start 2024-01-01 · record updated 2026-05-22
Sovateltide 4 open studies, 1 placebo-controlled
Sovateltide for the Treatment of Acute Traumatic Brain Injury
- Primary outcome
- Proportion of patients achieving a favorable functional outcome (GOS-E score ≥7) at Day 90 post-randomization. Score range: 1 to 8; higher scores represent a better outcome. (90 days)
- Where
- Not listed
- Sponsor (as registered)
- Pharmazz, Inc.
- Dates
- Start 2026-12 · record updated 2026-10-13
Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke
- Primary outcome
- Determine the efficacy of sovateltide in patients with acute cerebral ischemic stroke assessed by modified Rankin Scale (mRS) score of 0-2 at day 90 post-randomization. (Day 1 through Day 90)
- Where
- Australia, Germany, Spain, United Kingdom, United States
- Sponsor (as registered)
- Pharmazz, Inc.
- Dates
- Start 2025-07-24 · record updated 2026-11-13
Assess Safety and Efficacy of Sovateltide in Hypoxic-ischemic Encephalopathy
- Primary outcome
- Percentage of patients with death or disability (moderate/severe) (24 months)
- Where
- India
- Sponsor (as registered)
- Pharmazz, Inc.
- Dates
- Start 2023-09-06 · record updated 2025-12-31
PMZ-1620 (Sovateltide) in Patients of Acute Spinal Cord Injury
- Primary outcome
- Incidence of PMZ-1620 related adverse events (90 days) +1 more
- Where
- India
- Sponsor (as registered)
- Pharmazz, Inc.
- Dates
- Start 2019-01-10 · record updated 2025-07-04
Atosiban 3 open studies, 3 placebo-controlled
Atosiban in Women With Previous Implantation Failure and Abnormal Uterine Contractions
- Primary outcome
- Live birth (After 24 weeks of gestation)
- Where
- China
- Sponsor (as registered)
- Northwest Women's and Children's Hospital, Xi'an, Shaanxi
- Dates
- Start 2025-12-06 · record updated 2025-12-09
The Effect of Oral Oxytocin and Atosiban on Top-down Attention ( OTAtosiban )
- Primary outcome
- Error rates in prosaccade and antisaccade trials (Starting 45 minutes post-treatment subjects will complete the eye-tracking task with data on numbers of prosaccade and antisaccade errors being collected continuously over a period of 35 minutes.) +1 more
- Where
- China
- Sponsor (as registered)
- University of Electronic Science and Technology of China
- Dates
- Start 2025-09 · record updated 2025-09-08
The Effect of Oral Oxytocin and Atosiban on Social Attention
- Primary outcome
- Fixation duration (Fixation durations will be taken for each of the areas of interest in the four different visual paradigms starting 45 minutes post-treatment from the beginning of each paradigm until the end of each paradigm (each paradigm lasts around 10 minutes)) +1 more
- Where
- China
- Sponsor (as registered)
- University of Electronic Science and Technology of China
- Dates
- Start 2025-06-09 · record updated 2025-07-30
BNP 3 open studies, 2 placebo-controlled
rhBNP for Prevention of Cardiac Surgery-Associated Acute Kidney Injury (CSA-AKI)
- Primary outcome
- Incidence of acute kidney injury (AKI) within 7 days postoperatively, diagnosed per KDIGO criteria (Within 7 days after surgery, or until hospital discharge if earlier)
- Where
- China
- Sponsor (as registered)
- China National Center for Cardiovascular Diseases
- Dates
- Start 2026-05-01 · record updated 2026-06-01
Recombinant Human Brain Natriuretic Peptide for the Recovery Stage of Septic Shock
- Primary outcome
- The pressure gradient of venous return (From baseline to 30 minutes after rh-BNP initiation.)
- Where
- Not listed
- Sponsor (as registered)
- Sichuan Provincial People's Hospital
- Dates
- Start 2025-12 · record updated 2025-07-29
- Primary outcome
- Changes in blood pressure (BP) (48 hours, from day 1 to day 2. Specifically, it will be assessed before first injection(baseline data) up to 12 hours post last injection.)
- Where
- Norway
- Sponsor (as registered)
- Oslo University Hospital
- Dates
- Start 2015-12 · record updated 2018-01-03
This registry record has not been updated since 2018-01-03, so its "recruiting" status may be out of date.
Pegmolesatide 3 open studies
- Primary outcome
- Change of mean HB level (from baseline to 12 weeks and 16 weeks)
- Where
- China
- Sponsor (as registered)
- Guangdong Provincial People's Hospital
- Dates
- Start 2025-09-08 · record updated 2026-01-15
Pegmolesatide Treatment for Anemia in Patients Undergoing Long-term Dialysis
- Primary outcome
- The change in mean hemoglobin (Hb) levels from baseline at weeks 12 to 16 of treatment in the three groups. (During weeks 12 to 16 of the study treatment)
- Where
- China
- Sponsor (as registered)
- Chinese PLA General Hospital
- Dates
- Start 2025-08-01 · record updated 2025-09-12
- Primary outcome
- Changes of mean Hb levels from baseline in the standard medication regimen group and the optimized medication regimen group at week 24 of the treatment period. (the 24th week of treatment.)
- Where
- China
- Sponsor (as registered)
- The First Affiliated Hospital of Dalian Medical University
- Dates
- Start 2025-05-01 · record updated 2026-09-02
PSMA-1007 3 open studies
- Primary outcome
- Sensitivity and specificity of [18F]PSMA-1007 PET/CT for the detection of pelvic nodal disease (N1) compared to histology as the standard of reference (6 to 8 weeks post-surgery)
- Where
- France, Germany, Italy, Japan, Netherlands, Spain
- Sponsor (as registered)
- ABX advanced biochemical compounds GmbH
- Dates
- Start 2024-06-13 · record updated 2026-11-04
The Exploration of 18F-PSMA-1007 PET/CT Imaging in Prostate Cancer Patients
- Primary outcome
- 18F-PSMA-1007 PET/CT and 18F-FDG PCT/CT imaging were compared to determine the advantages of 18F-PSMA-PSMA PET/CT imaging for prostate cancer (1 day)
- Where
- China
- Sponsor (as registered)
- Affiliated Hospital of Jiangnan University
- Dates
- Start 2024-01-25 · record updated 2025-01-24
18F-PSMA-1007 PET/CT in Prostate Cancer - Access Trial 2022 to 2028
- Primary outcome
- Safety - immediate (Immediately after tracer injection) +3 more
- Where
- Canada
- Sponsor (as registered)
- University of Alberta
- Dates
- Start 2023-07-25 · record updated 2026-09-24
ANP 2 open studies, 1 placebo-controlled
- Primary outcome
- modified Rankin scale (mRS) scores (180 days)
- Where
- Not listed
- Sponsor (as registered)
- Fudan University
- Dates
- Start 2026-10-01 · record updated 2026-08-26
- Primary outcome
- changes in the NIHSS score (after 14 days of randomization)
- Where
- China
- Sponsor (as registered)
- Nanjing Medical University
- Dates
- Start 2025-01-01 · record updated 2024-12-12
Corifollitropin alfa 2 open studies
- Primary outcome
- To compare the number of total oocytes obtained after controlled ovarian stimulation with α-Corifolitropin vs. β-Folitropin in donors in whom medroxyprogesterone acetate (MPA) was used to prevent early luteinization. (2 years) +1 more
- Where
- Spain
- Sponsor (as registered)
- Instituto Valenciano de Infertilidad, IVI VALENCIA
- Dates
- Start 2025-07-08 · record updated 2025-09-15
PPOS (Progestin Primed Ovarian Stimulation) and Corifollitropin Alfa (CFA) Cross-over Study
- Primary outcome
- Treatment-related quality of life and patient satisfaction after comparing two different ovulation stimulation cycles (Six months)
- Where
- Belgium
- Sponsor (as registered)
- University Hospital, Ghent
- Dates
- Start 2025-01-27 · record updated 2025-12-26
Emodepside 2 open studies, 1 placebo-controlled
- Primary outcome
- Cure rate (CR) of emodepside compared to albendazole against Trichuris incognita (Between 14-21 days post-treatment)
- Where
- Not listed
- Sponsor (as registered)
- Jennifer Keiser
- Dates
- Start 2026-11-15 · record updated 2026-08-14
Efficacy and Safety of Emodepside in Participants With Soil-transmitted Helminth Infections
- Primary outcome
- Cured of T. trichiura infection (Test of Cure Visit at 14 to 21 days after end of treatment)
- Where
- Philippines
- Sponsor (as registered)
- Swiss Tropical & Public Health Institute
- Dates
- Start 2026-11-06 · record updated 2026-08-14
Albuvirtide 1 open study
Optimization of Antiretroviral Therapy in Patients With AIDS-Related Lymphoma
- Primary outcome
- Virological Suppression Rate at Week 24 (Week 24)
- Where
- China
- Sponsor (as registered)
- Shanghai Public Health Clinical Center
- Dates
- Start 2026-05-26 · record updated 2026-07-27
Aprotinin 1 open study, 1 placebo-controlled
Clinical Trial With Aprotinin in the Acute Respiratory Distress Syndrome Treatment
- Primary outcome
- Ventilator-Free Days (VFD) in patients with moderate or severe ARDS (From first dose up to Day 28)
- Where
- Spain
- Sponsor (as registered)
- Fundacion del Hospital Nacional de Paraplejicos para la Investigacion y la Integracion
- Dates
- Start 2026-06-18 · record updated 2026-07-15
Beinaglutide 1 open study
- Primary outcome
- The proportion of subjects achieving HbA1c <7.0%, no weight increase (≤0 kg), and no hypoglycemia (blood glucose ≤3.9 mmol/L or severe hypoglycemia) after 8 weeks of treatment. (From baseline to the end of treatment at 8 week)
- Where
- China
- Sponsor (as registered)
- Beijing Hospital
- Dates
- Start 2019-07-02 · record updated 2025-05-02
Buserelin 1 open study
- Primary outcome
- Morbidity Outcomes (after the initial 100 patients have had a median follow up of at least three years and then every year.)
- Where
- United States
- Sponsor (as registered)
- Proton Collaborative Group
- Dates
- Start 2012-01 · record updated 2026-09-29
Carnosine 1 open study
Effects of Carnosine In Patients With Peripheral Arterial Disease Patients
- Primary outcome
- Measure distance covered on six-minute walk test (6MWT) (Baseline, 3 months, 6 months, 9 months)
- Where
- United States
- Sponsor (as registered)
- Shahid Baba
- Dates
- Start 2025-05-20 · record updated 2026-11-17
Mifamurtide 1 open study
- Primary outcome
- Event-Free Survival (EFS) (10,3 months)
- Where
- Poland
- Sponsor (as registered)
- Anna Raciborska
- Dates
- Start 2026-04-01 · record updated 2026-10-07
Tertomotide 1 open study, 1 placebo-controlled
GV1001 Subcutaneous for the Treatment of Moderate to Severe Alzheimer's Disease(AD)
- Primary outcome
- Change from baseline in SIB(Severe Impairment Battery) score after GV1001 administration for 24 weeks (Baseline, Week 26) +1 more
- Where
- Not listed
- Sponsor (as registered)
- Samsung Pharmaceutical Co., Ltd.
- Dates
- Start 2027-07 · record updated 2026-06-10
Testagen 1 open study
Product Transference Study of Testagen™ TDS®-Testosterone
- Primary outcome
- Transference of Topical Testosterone from Dosed Males to Female Partners As Measured by net change from Baseline of Serum Testosterone in nG/dL expressed as Maximum Serum Concentration or Cmax. (30 minutes to 24 hours post dose)
- Where
- Not listed
- Sponsor (as registered)
- Transdermal Delivery Solutions Corp
- Dates
- Start 2027-01-05 · record updated 2026-05-27
Thymosin α1 1 open study
- Primary outcome
- The mean Sequential Organ Failure Assessment (SOFA) score of 7 days after surgery (within the prior 7 days after surgery.)
- Where
- China
- Sponsor (as registered)
- Nanjing Medical University
- Dates
- Start 2025-04-01 · record updated 2026-01-14
Approved peptide drugs in new trials (106)
Drugs the FDA has already approved for something, now being tested for other uses, doses or combinations. One row each: how many open studies, how many are phase 3 or placebo-controlled, and a link to the full list on the registry.
How this list is made
For each of the 416 encyclopedia peptides that have any registered trial, we ask ClinicalTrials.gov (API version 2) for studies whose status is recruiting, not yet recruiting, or enrolling by invitation, searching by intervention name. The registry's search is fuzzy, so a study is kept only if the peptide's name or one of its recorded aliases is listed as an intervention the study gives (a drug, biologic, supplement or radiopharmaceutical), and not as part of another thing's name: a "GLP-1 receptor agonist", a "CGRP antibody" or a "BNP level" is not native GLP-1, CGRP or BNP. "Compared with" reads the study's arm types and intervention names: a placebo or sham arm counts as placebo, an active-comparator arm as an active drug. Sponsor names are shown as the sponsor registered them; listing a sponsor is not an endorsement, and the registry does not check that a sponsor's product is what it says. A record its sponsor has not updated in 2 years is flagged, because the registry's status is only as current as the sponsor keeps it. A failed registry request is recorded as an error and blocks the page from rebuilding, so an outage is never shown as "no trials". The list is re-read at least every 45 days. See the trials and outcomes tracker for how far each peptide got, including the ones that failed.